: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription

Articles published in Aliment Pharmacol Ther
Retrieve available abstracts of 442 articles:
HTML format

Single Articles

August 2026

VISSER EH, Voshaar MAO, van Linschoten RCA, Bodelier AGL, et al
A Care Pathway for the Treatment of IBD Reduces Healthcare Costs and Is Cost-Effective: Results of the Multicentre IBD Value Study.
Aliment Pharmacol Ther. 2026;64:313-325.
PubMed Abstract available

July 2026

ETCHEGARAY A, Goetz N, Hanigan K, Phillips J, et al
Lowering the C-Reactive Protein (CRP) Threshold Improves Risk Stratification in Acute Ulcerative Colitis: A Propensity-Matched Analysis.
Aliment Pharmacol Ther. 2026 Jul 18. doi: 10.1111/apt.70825.
PubMed Abstract available

RICHARD N, Fumery M
Letter: Upadacitinib in Perianal Crohn's Disease: Does Clinical Closure Reflect True Remission? Authors' Reply.
Aliment Pharmacol Ther. 2026 Jul 15. doi: 10.1111/apt.70847.
PubMed

MARTINEZ AS, Mercader PM, Cuquerella JT, Watts MMB, et al
Impact of Inflammatory Activity on Anorectal Function in Patients With Ulcerative Colitis: A Prospective Study.
Aliment Pharmacol Ther. 2026 Jul 15. doi: 10.1111/apt.70855.
PubMed Abstract available

SATTAYALERTYANYONG O, Nugent Z, Barr B, Bernstein KN, et al
Inflammatory Bowel Disease Is Associated With an Increased Risk of End-Stage Renal Disease: A Population-Based Cohort Study.
Aliment Pharmacol Ther. 2026 Jul 14. doi: 10.1111/apt.70845.
PubMed Abstract available

Correction to 'Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial'.
Aliment Pharmacol Ther. 2026 Jul 14. doi: 10.1111/apt.70861.
PubMed

ERNEST-SUAREZ K, Hoentjen F
Editorial: Risankizumab in Refractory Crohn's Disease-From Real-World Effectiveness to Strategic Positioning and Early Monitoring.
Aliment Pharmacol Ther. 2026 Jul 13. doi: 10.1111/apt.70858.
PubMed

BATRA G, Shukla A, Chatterjee A, Chandnani S, et al
Meta-Analysis: Crohn's Disease Exclusion Diet for Induction and Maintenance in Crohn's Disease.
Aliment Pharmacol Ther. 2026 Jul 12. doi: 10.1111/apt.70857.
PubMed Abstract available

YOUNG D, Booker C, Samaan M, Kok K, et al
Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group.
Aliment Pharmacol Ther. 2026 Jul 9. doi: 10.1111/apt.70833.
PubMed Abstract available

ZHU A, Segal JP
Letter: Nuanced Interpretation of Faecal Calprotectin During Maintenance of Ulcerative Colitis Treatment: Sweet Spots and Pitfalls.
Aliment Pharmacol Ther. 2026 Jul 9. doi: 10.1111/apt.70839.
PubMed

ELDESOUKI MH, Ibrahim A, Marey MM, Francis FF, et al
Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis.
Aliment Pharmacol Ther. 2026 Jul 3. doi: 10.1111/apt.70779.
PubMed Abstract available

COLLINS K, Kamath S, Davis RH, Costello SP, et al
Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy.
Aliment Pharmacol Ther. 2026 Jul 1. doi: 10.1111/apt.70826.
PubMed Abstract available

June 2026

TANG CZ, Faye AS
Letter: Does the Association Between Mild Endoscopic Activity and Adverse Outcomes Justify Treatment Escalation in Older Adults With Inflammatory Bowel Disease? Authors' Reply.
Aliment Pharmacol Ther. 2026 Jun 22. doi: 10.1111/apt.70822.
PubMed

RICHARD N, Fumery M
Editorial: Upadacitinib in Perianal Crohn's Disease. Authors' Reply.
Aliment Pharmacol Ther. 2026 Jun 20. doi: 10.1111/apt.70817.
PubMed

QIU L, Tang J, Yue C
Letter: Does the Association Between Mild Endoscopic Activity and Adverse Outcomes Justify Treatment Escalation in Older Adults With Inflammatory Bowel Disease?
Aliment Pharmacol Ther. 2026 Jun 19. doi: 10.1111/apt.70804.
PubMed

SAWARD G, Heerasing N
Letter: Upadacitinib in Perianal Crohn's Disease: Does Clinical Closure Reflect True Remission?
Aliment Pharmacol Ther. 2026 Jun 18. doi: 10.1111/apt.70815.
PubMed

BOKEMEYER A, Tran F, Plachta-Danielzik S, Gilman E, et al
Comparative Real-World Effectiveness of Anti-TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA-IBD Registry in Germany.
Aliment Pharmacol Ther. 2026 Jun 15. doi: 10.1111/apt.70796.
PubMed Abstract available

VISSER EH, Voshaar MAO, van Linschoten RCA, Bodelier AGL, et al
Editorial: Inflammatory Bowel Disease Care Pathways-Improving Quality, but Not at Increased Cost. Authors' Reply.
Aliment Pharmacol Ther. 2026 Jun 10. doi: 10.1111/apt.70780.
PubMed

BARREIRO-DE ACOSTA M, Zabana Y, Nieto-Garcia L, Poncela M, et al
Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.
Aliment Pharmacol Ther. 2026 Jun 10. doi: 10.1111/apt.70783.
PubMed Abstract available

KOPPELMAN LJM, Loveikyte R, Goetgebuer RL, van der Marel S, et al
Clinical Trial: Predicting Response to Iron Therapy in Patients With Active Inflammatory Bowel Disease Using Hepcidin and Functional Iron Indices: A Multicentre Randomised Trial.
Aliment Pharmacol Ther. 2026 Jun 8. doi: 10.1111/apt.70775.
PubMed Abstract available

DUBE LR, Sorin M, Allez M, Afif W, et al
The Association of Faecal Calprotectin Measurements With Endo-Histological Remission in Ulcerative Colitis: A Pooled Analysis.
Aliment Pharmacol Ther. 2026 Jun 2. doi: 10.1111/apt.70735.
PubMed Abstract available

GOYAL MK, Bishu S
Editorial: Upadacitinib in Perianal Crohn's Disease.
Aliment Pharmacol Ther. 2026 Jun 2. doi: 10.1111/apt.70759.
PubMed

GOYAL MK, Srivastava H, Sehgal T, Bishu S, et al
Review Article: TL1A Inhibitors in IBD - Mechanistic Rationale and Clinical Evidence.
Aliment Pharmacol Ther. 2026;63:1458-1473.
PubMed Abstract available

May 2026

GARCIA JLR, Suarez-Ferrer C, Zabana Y
Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply.
Aliment Pharmacol Ther. 2026 May 12. doi: 10.1111/apt.70715.
PubMed

BURR N
Editorial: Inflammatory Bowel Disease Care Pathways-Improving Quality, but Not at Increased Cost.
Aliment Pharmacol Ther. 2026 May 11. doi: 10.1111/apt.70726.
PubMed

April 2026

GARCIA JLR, Suarez-Ferrer C, Zabana Y
Editorial: Beyond Resection-Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply.
Aliment Pharmacol Ther. 2026 Apr 27. doi: 10.1111/apt.70702.
PubMed

RICHARD N, Seksik P, Altwegg R, Nachury M, et al
One-Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real-World GETAID Study.
Aliment Pharmacol Ther. 2026 Apr 27. doi: 10.1111/apt.70682.
PubMed Abstract available

LI J
Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease.
Aliment Pharmacol Ther. 2026 Apr 25. doi: 10.1111/apt.70700.
PubMed

FONS AB, Asscher VER, Mooijaart SP, Maljaars PWJ, et al
Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply.
Aliment Pharmacol Ther. 2026 Apr 25. doi: 10.1111/apt.70660.
PubMed

RIGGOTT C, Fairbrass KM, Guthrie EA, Black CJ, et al
Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease-A Core Phenotype Beyond Inflammatory Activity. Authors' Reply.
Aliment Pharmacol Ther. 2026 Apr 17. doi: 10.1111/apt.70673.
PubMed

BERTIN L, Savarino EV
Letter: Beyond the Mucosa-Strengthening the Case for Transmural Healing as a Monitoring Target in Crohn's Disease.
Aliment Pharmacol Ther. 2026 Apr 17. doi: 10.1111/apt.70674.
PubMed

MURTHY SK
Letter: Are All Extra-Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply.
Aliment Pharmacol Ther. 2026 Apr 16. doi: 10.1111/apt.70679.
PubMed

SINGH AK, Birda CL
Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease-Expanding Strategies Beyond Double-Dose Recombinant Vaccination. Authors' Reply.
Aliment Pharmacol Ther. 2026 Apr 15. doi: 10.1111/apt.70687.
PubMed

WANG R, Cao D, Cui Z
Editorial-Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease. Authors' Reply.
Aliment Pharmacol Ther. 2026 Apr 15. doi: 10.1111/apt.70672.
PubMed

ARATARI A, Festa S
Editorial: Beyond Resection-Rethinking Postoperative Management in Colonic Crohn's Disease.
Aliment Pharmacol Ther. 2026 Apr 15. doi: 10.1111/apt.70680.
PubMed

FONS AB, Maljaars PWJ
Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply.
Aliment Pharmacol Ther. 2026 Apr 14. doi: 10.1111/apt.70681.
PubMed

KUMAR A, Patil AN, Sharma V
Letter: Steroid Tapering in Ulcerative Colitis-The Importance of Disease Severity and Maintenance Therapy. Authors' Reply.
Aliment Pharmacol Ther. 2026 Apr 8. doi: 10.1111/apt.70661.
PubMed

O'CONNOR R, Karunadasa H, Vasudevan A
Letter: Steroid Tapering in Ulcerative Colitis: The Importance of Disease Severity and Maintenance Therapy.
Aliment Pharmacol Ther. 2026 Apr 5. doi: 10.1111/apt.70642.
PubMed

YZET C, Plancke A, Brazier F, Grados L, et al
Intestinal Ultrasound Transmural Healing Was Associated With Improved Long-Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study.
Aliment Pharmacol Ther. 2026;63:992-999.
PubMed Abstract available

March 2026

HEGDE Y, Caldera F
Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease - Expanding Strategies Beyond Double-Dose Recombinant Vaccination.
Aliment Pharmacol Ther. 2026 Mar 31. doi: 10.1111/apt.70651.
PubMed

JIAO L, Cao Y
Letter: Are All Extra-Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
Aliment Pharmacol Ther. 2026 Mar 31. doi: 10.1111/apt.70650.
PubMed

BARBERIO B, Savarino EV
Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity.
Aliment Pharmacol Ther. 2026 Mar 31. doi: 10.1111/apt.70641.
PubMed

ALSOUDANI A, Swaminathan A
Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease.
Aliment Pharmacol Ther. 2026 Mar 30. doi: 10.1111/apt.70640.
PubMed

LIU C, He D, Wei A, Xu L, et al
Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2026 Mar 19. doi: 10.1111/apt.70632.
PubMed

KUMAR A, Patil A, Sharma V
Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply.
Aliment Pharmacol Ther. 2026 Mar 19. doi: 10.1111/apt.70624.
PubMed

SALUJA H, Chinnaratha MA
Letter: Is Short Tapering of Steroids in Moderate to Severely Active Ulcerative Colitis Really Inferior to a Long Steroid Taper, or Just Underpowered to Reach a Definitive Conclusion?
Aliment Pharmacol Ther. 2026 Mar 18. doi: 10.1111/apt.70633.
PubMed

CARBERY I, Selinger CP
Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty?
Aliment Pharmacol Ther. 2026 Mar 18. doi: 10.1111/apt.70621.
PubMed

SAWARD G, Segal J
Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis.
Aliment Pharmacol Ther. 2026 Mar 18. doi: 10.1111/apt.70617.
PubMed

REJI R, Novak K
Editorial: "Striding" Towards Transmural Healing: Redefining Deep Remission as a Treatment Target in Crohn's Disease.
Aliment Pharmacol Ther. 2026 Mar 17. doi: 10.1111/apt.70513.
PubMed

RUEDA GARCIA JL, Suarez Ferrer C, Garcia de la Filia Molina I, Rivas C, et al
Post-Operative Recurrence of Colonic Crohn's Disease After Colectomy: The RESECOL Study by the Young Group of GETECCU.
Aliment Pharmacol Ther. 2026 Mar 12. doi: 10.1111/apt.70608.
PubMed Abstract available

VAN WEES JC, Little RD, Melton SL
Letter: Eating Disorders in Inflammatory Bowel Disease-Are We Asking the Right Questions?
Aliment Pharmacol Ther. 2026 Mar 10. doi: 10.1111/apt.70582.
PubMed

FONS AB, Asscher VER, Stuyt RJL, Baven-Pronk AMC, et al
Frailty Is Associated With All-Cause and Acute Hospitalisations During 18 Months Follow-Up in Older Patients With Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2026 Mar 8. doi: 10.1111/apt.70594.
PubMed Abstract available

WANG R, Wu Y, Xu D, Yang Y, et al
Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease.
Aliment Pharmacol Ther. 2026 Mar 3. doi: 10.1111/apt.70600.
PubMed Abstract available

AHUJA D, Park SK, Yeh KH, Patel SB, et al
Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases.
Aliment Pharmacol Ther. 2026;63:686-695.
PubMed Abstract available

AHUJA D, Yeh KH, Patel SB, Park SK, et al
Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions-A U.S. Claims-Based Study.
Aliment Pharmacol Ther. 2026;63:885-887.
PubMed Abstract available

FAYE AS, Axelrad J, Sun J, Halfvarsson J, et al
Treatment-Free Outcomes Following Surgery for IBD: A Nationwide Cohort Study.
Aliment Pharmacol Ther. 2026;63:821-837.
PubMed Abstract available

February 2026

MEDAWAR E, Chaudhary H, Zoughlami A, Ekhdoura M, et al
Systematic Review of Published Guidelines: Recommendations for Exams Under Anaesthesia, Seton Insertion and Timing of Seton Removal for Perianal and Rectovaginal Fistulising Crohn's Disease.
Aliment Pharmacol Ther. 2026 Feb 16. doi: 10.1111/apt.70569.
PubMed Abstract available

ALSAKARNEH S, Tome J, Farraye FA, Pardi DS, et al
Research Communication: Comparative Effectiveness of Ustekinumab and Vedolizumab in the Management of Chronic Pouchitis-A Population-Based Study.
Aliment Pharmacol Ther. 2026;63:424-428.
PubMed Abstract available

January 2026

PATIL AN, Kumar A, Sharma V
Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis. Authors' Reply.
Aliment Pharmacol Ther. 2026 Jan 29. doi: 10.1111/apt.70552.
PubMed

BHAT G, Shetty A
Letter: A Patient Centric Approach to Tapering Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis.
Aliment Pharmacol Ther. 2026 Jan 28. doi: 10.1111/apt.70546.
PubMed

KUMAR A, Patil AN, Grewal J, Kumaravel J, et al
Clinical Trial: Long Versus Short Tapering of Steroids in Steroid Responsive Moderate to Severely Active Ulcerative Colitis-A Randomised Controlled Trial.
Aliment Pharmacol Ther. 2026 Jan 2. doi: 10.1111/apt.70509.
PubMed Abstract available

LU C, Verstockt B, Winter MW, Christensen B, et al
Review Article: Extending the Frontiers of Intestinal Ultrasound Knowledge, Performance and Expansion.
Aliment Pharmacol Ther. 2026;63:40-56.
PubMed Abstract available

ATTAUABI M, Madsen GR, Bendtsen F, Seidelin JB, et al
Research Communication: Sexual Dysfunction is a Common Early Challenge in Newly Diagnosed Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2026;63:288-293.
PubMed Abstract available

December 2025

GODDARD Q, Markovinovic A, Ronksley PE, Seow C, et al
Meta-Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Dec 27. doi: 10.1111/apt.70492.
PubMed Abstract available

GIRI S, Jena A, Sharma V, Sebastian S, et al
Editorial: The Hidden Burden-Stigmatisation in Inflammatory Bowel Disease: Authors' Reply.
Aliment Pharmacol Ther. 2025 Dec 21. doi: 10.1111/apt.70507.
PubMed

LENTI MV, Santacroce G, Di Sabatino A
Editorial: The Hidden Burden-Stigmatisation in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Dec 21. doi: 10.1111/apt.70478.
PubMed

November 2025

MARACLE B, Quan S, Hamilton P, Shaikh A, et al
Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP-1 Receptor Agonists in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Nov 30. doi: 10.1111/apt.70485.
PubMed Abstract available

SODERHOLM JD
Editorial: The Appendix-A Dead End for Treating Ulcerative Colitis, After All?
Aliment Pharmacol Ther. 2025 Nov 25. doi: 10.1111/apt.70370.
PubMed

DERKS MEW, Hoentjen F
Editorial: High-Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer-Authors' Reply.
Aliment Pharmacol Ther. 2025 Nov 24. doi: 10.1111/apt.70473.
PubMed

HICKEY A, Dong C, Lamb CA
Editorial: High-Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer.
Aliment Pharmacol Ther. 2025 Nov 24. doi: 10.1111/apt.70442.
PubMed

SINGH AK, Soni RK, Jearth V, Yadav AI, et al
Clinical Trial: Immunogenicity of Double-Dose Versus Standard-Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Nov 20. doi: 10.1111/apt.70470.
PubMed Abstract available

LEE JD, Papamichael K, Grinspan LT, Cheifetz AS, et al
Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease-Authors' Reply.
Aliment Pharmacol Ther. 2025 Nov 17. doi: 10.1111/apt.70467.
PubMed

CHUNG Y, Nayagam JS
Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease.
Aliment Pharmacol Ther. 2025 Nov 17. doi: 10.1111/apt.70444.
PubMed

BAILLIE S, Blackwell J, Pollok R
Letter: From Descriptive Epidemiology to Clinical Imperative-Challenging the Paradigm of Pain and Sedative Use in Inflammatory Bowel Disease. Authors' Reply.
Aliment Pharmacol Ther. 2025 Nov 12. doi: 10.1111/apt.70459.
PubMed

YANG D, Yang J, Wang S, Wang G, et al
Letter: From Descriptive Epidemiology to Clinical Imperative-Challenging the Paradigm of Pain and Sedative Use in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Nov 12. doi: 10.1111/apt.70416.
PubMed

MURTHY SK, Ahmed F, Pugliese M, Taljaard M, et al
A Population-Based Matched Cohort Study of Extra-Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Nov 11. doi: 10.1111/apt.70439.
PubMed Abstract available

GIRI S, Harindranath S, Chandnani S, Jena A, et al
Systematic Review: Stigma Associated With Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Nov 4. doi: 10.1111/apt.70448.
PubMed Abstract available

PATEL P, Belesiotis P, Rai NS, Yuan Y, et al
Meta-Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Nov 4. doi: 10.1111/apt.70446.
PubMed Abstract available

October 2025

DERKS MEW, Te Groen M, Derikx LAAP, Nagtegaal ID, et al
High Risk of Colorectal Cancer After High-Grade Dysplasia in Inflammatory Bowel Disease Patients.
Aliment Pharmacol Ther. 2025 Oct 24. doi: 10.1111/apt.70429.
PubMed Abstract available

LEE JD, Papamichael K, Grinspan LT, Cheifetz AS, et al
Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease.
Aliment Pharmacol Ther. 2025 Oct 23. doi: 10.1111/apt.70425.
PubMed Abstract available

RIGGOTT C, Fairbrass KM, Guthrie EA, Black CJ, et al
Persistence of Symptoms of Anxiety and Depression in Inflammatory Bowel Disease: A Longitudinal Follow-Up Study.
Aliment Pharmacol Ther. 2025 Oct 21. doi: 10.1111/apt.70431.
PubMed Abstract available

ROUVEYRE R, Coudol S, Collins M, de Maissin A, et al
Clinical Trial: Simplified Bowel Preparation for Small Bowel Capsule Endoscopy in Crohn's Disease.
Aliment Pharmacol Ther. 2025 Oct 20. doi: 10.1111/apt.70417.
PubMed Abstract available

TANG CZ, Delau OR, Katz S, Axelrad JE, et al
Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Oct 15. doi: 10.1111/apt.70414.
PubMed Abstract available

ELFORD AT, Constantine-Cooke N, Jenkinson PW, Gros B, et al
Twenty-Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, Scotland.
Aliment Pharmacol Ther. 2025;62:699-709.
PubMed Abstract available

September 2025

POLLOK R
Letter: Temporal Trends in the Rate of Colectomy in Ulcerative Colitis.
Aliment Pharmacol Ther. 2025 Sep 30. doi: 10.1111/apt.70368.
PubMed

MATHIAS RM, Bogatic D, Bryant RV
Editorial: Is Disease Clearance the Target in Ulcerative Colitis or a Stride Too Far?
Aliment Pharmacol Ther. 2025 Sep 26. doi: 10.1111/apt.70291.
PubMed

MASSIRONI S, Zilli A, Furfaro F, Allocca M, et al
Systematic Review: Ultrasound Goes Echo-Decarbonising Inflammatory Bowel Disease Care Through Intestinal Ultrasound.
Aliment Pharmacol Ther. 2025 Sep 23. doi: 10.1111/apt.70385.
PubMed Abstract available

RUBIN DE CELIX C, Chaparro M, Gisbert JP
Editorial: Managing the Moving Target-Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply.
Aliment Pharmacol Ther. 2025 Sep 17. doi: 10.1111/apt.70379.
PubMed

CLARK N, Tassone D, Ding NS
Editorial: Managing the Moving Target-Dose Adjustments in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Sep 17. doi: 10.1111/apt.70340.
PubMed

NATT N, Gindi M, Dela Cruz GR, Ponich T, et al
IL23 Receptor Polymorphism Is a Predictor of Anti-Tumour Necrosis Factor-alpha-Induced Paradoxical Psoriasis in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Sep 16. doi: 10.1111/apt.70377.
PubMed Abstract available

NORDESTGAARD RLM, Lo B, Bergstrom R, Adzioski I, et al
Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5-Aminosalicylate for Ulcerative Colitis-The EASI Trial.
Aliment Pharmacol Ther. 2025 Sep 16. doi: 10.1111/apt.70375.
PubMed Abstract available

LE COSQUER G, Laharie D
Editorial: Ulcerative Colitis Management in the Biologic Era-Data From the English Healthcare Databases.
Aliment Pharmacol Ther. 2025 Sep 11. doi: 10.1111/apt.70346.
PubMed

SINGH M, Grover M, Petrik M
Letter: Multidisciplinary Approach for Inflammatory Bowel Disease to Promote Value-Based Care.
Aliment Pharmacol Ther. 2025 Sep 9. doi: 10.1111/apt.70369.
PubMed

COUCH J, Thomas K, Card TR, Humes DJ, et al
Editorial: Ulcerative Colitis Management in the Biologic Era-Data From the English Healthcare Databases. Authors' Reply.
Aliment Pharmacol Ther. 2025 Sep 8. doi: 10.1111/apt.70362.
PubMed

August 2025

MAHADEVAN U, Seow CH, Barnes EL, Chaparro M, et al
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Aug 28. doi: 10.1111/apt.70290.
PubMed Abstract available

RANJAN MK, Vuyyuru SK
Editorial: Corticosteroid Responsive Acute Severe Ulcerative Colitis-Revisiting Maintenance Approaches in the Era of Advanced Therapies.
Aliment Pharmacol Ther. 2025 Aug 26. doi: 10.1111/apt.70288.
PubMed

LIN KJ, Hung CH, Wei JC
Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns.
Aliment Pharmacol Ther. 2025 Aug 23. doi: 10.1111/apt.70311.
PubMed

OSOOLI M, Olen O
Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns. Authors' Reply.
Aliment Pharmacol Ther. 2025 Aug 23. doi: 10.1111/apt.70356.
PubMed

BAYOUMY AB, de Boer NK
Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis-Hope Beyond Monotherapy.
Aliment Pharmacol Ther. 2025 Aug 15. doi: 10.1111/apt.70318.
PubMed

NEELAM PB, Banerjee R
Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis-Hope Beyond Monotherapy. Authors' Reply.
Aliment Pharmacol Ther. 2025 Aug 15. doi: 10.1111/apt.70339.
PubMed

COUCH J, Thomas K, Card TR, Humes DJ, et al
Temporal Trends in Medical and Surgical Management of Ulcerative Colitis in England: 2003-2020.
Aliment Pharmacol Ther. 2025 Aug 8. doi: 10.1111/apt.70319.
PubMed Abstract available

RUBIN DE CELIX C, Ricart E, Martin-Arranz MD, de Francisco R, et al
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA.
Aliment Pharmacol Ther. 2025 Aug 8. doi: 10.1111/apt.70312.
PubMed Abstract available

NEELAM PB, Mekala D, Patel R, Banerjee R, et al
Efficacy and Safety of Vedolizumab and Tofacitinib (VETO) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti-TNF and a Second-Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial.
Aliment Pharmacol Ther. 2025 Aug 4. doi: 10.1111/apt.70309.
PubMed Abstract available

UZZAN M, Laharie D, Kirchgesner J
Editorial: JAK to JAK-Navigating Intra-Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply.
Aliment Pharmacol Ther. 2025;62:460-461.
PubMed

July 2025

AKIYAMA S
Editorial: Evolving Trends in Ulcerative Colitis Management-Insights From the Lothian Cohort.
Aliment Pharmacol Ther. 2025 Jul 30. doi: 10.1111/apt.70249.
PubMed

SHEHAB M, Alrashed F, Alrashidi A, Hassan A, et al
Network Meta-Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease.
Aliment Pharmacol Ther. 2025 Jul 27. doi: 10.1111/apt.70295.
PubMed Abstract available

ALSAKARNEH S, Aburumman R, Bilal M, Faye AS, et al
Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi-Centre Propensity Score Matched Analysis.
Aliment Pharmacol Ther. 2025 Jul 24. doi: 10.1111/apt.70303.
PubMed Abstract available

DALAL RS, Clarke LM, Cabral HJ, Carlin AD, et al
Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series.
Aliment Pharmacol Ther. 2025 Jul 24. doi: 10.1111/apt.70298.
PubMed Abstract available

LUNDQVIST E, Westberg K, Boman SE, Myrberg IH, et al
Outcome After Surgery for Colon Cancer in a National Cohort of Patients With and Without Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Jul 22. doi: 10.1111/apt.70296.
PubMed Abstract available

MARK-CHRISTENSEN A, Kristiansen EB, Laurberg S, Erichsen R, et al
Appendectomy Is Not Associated With a Milder Clinical Course of Ulcerative Colitis: A Nationwide Danish Population-Based Study.
Aliment Pharmacol Ther. 2025 Jul 21. doi: 10.1111/apt.70279.
PubMed Abstract available

RIGGOTT C, Gracie DJ, Ford AC
Editorial on 'Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort'. Authors' Reply.
Aliment Pharmacol Ther. 2025 Jul 18. doi: 10.1111/apt.70293.
PubMed

LORES T, Keefer L
Editorial on 'Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort'.
Aliment Pharmacol Ther. 2025 Jul 18. doi: 10.1111/apt.70272.
PubMed

DANESE S, Leong RW, Sands BE, Ma T, et al
Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis.
Aliment Pharmacol Ther. 2025 Jul 16. doi: 10.1111/apt.70264.
PubMed Abstract available

CHIN S, Con D, Hilley P, Corte C, et al
Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation.
Aliment Pharmacol Ther. 2025 Jul 15. doi: 10.1111/apt.70283.
PubMed Abstract available

KOCHAR B, Ananthakrishnan A
Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply.
Aliment Pharmacol Ther. 2025 Jul 11. doi: 10.1111/apt.70274.
PubMed

COATES MD, Yadav S, Bielefeldt K
Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
Aliment Pharmacol Ther. 2025 Jul 11. doi: 10.1111/apt.70258.
PubMed

CHETWOOD JD, Arzivian A, Tran Y, Paramsothy S, et al
Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Jul 10. doi: 10.1111/apt.70267.
PubMed Abstract available

CLOUGH J, Patel K, Honap S
Editorial: JAK to JAK-Navigating Intraclass JAK Inhibitor Switching in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Jul 9. doi: 10.1111/apt.70226.
PubMed

CHEN L, Srinivasan A, Choy SW, Van J, et al
Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide.
Aliment Pharmacol Ther. 2025 Jul 2. doi: 10.1111/apt.70262.
PubMed Abstract available

BAILLIE S, Saxena S, Jayasooriya N, Bottle A, et al
Pain and Sedative Medication Use Among Individuals With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study.
Aliment Pharmacol Ther. 2025 Jul 2. doi: 10.1111/apt.70247.
PubMed Abstract available

June 2025

RIGGOTT C, Gracie DJ, Ford AC
Prevalence and Predictors of Symptoms of Anxiety or Depression at Diagnosis in Patients With Inflammatory Bowel Disease: An Inception Cohort.
Aliment Pharmacol Ther. 2025 Jun 29. doi: 10.1111/apt.70248.
PubMed Abstract available

ROBERTS C, Peters J, Sazonvos A, Goodman N, et al
Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource.
Aliment Pharmacol Ther. 2025 Jun 23. doi: 10.1111/apt.70232.
PubMed Abstract available

SINGH A, Bhardwaj A, Sharma R, Singh D, et al
Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid-Responsive Acute Severe Ulcerative Colitis.
Aliment Pharmacol Ther. 2025 Jun 20. doi: 10.1111/apt.70246.
PubMed Abstract available

LIM J, Rezaie A
Editorial: Shooting in the Dark-The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Jun 16. doi: 10.1111/apt.70218.
PubMed

KOCHAR B, Chaaban L, Kobeissi L, Fuss A, et al
Outcomes Associated With Anti-Depressant Use in Patients With Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Jun 7. doi: 10.1111/apt.70229.
PubMed Abstract available

NARDONE OM, Noor NM, Prabhu A, Lim A, et al
The Effectiveness of Medical Therapies for Joint, Skin and Eye Extraintestinal Manifestations in IBD-An Umbrella Review.
Aliment Pharmacol Ther. 2025;61:1854-1871.
PubMed Abstract available

OSOOLI M, Voghera S, Bruze G, Nordenvall C, et al
Higher Prescribed Opioid Use Among Adults With Crohn's Disease Than General Population: A Nationwide Cohort Study in Sweden 2006-2021.
Aliment Pharmacol Ther. 2025 Jun 1. doi: 10.1111/apt.70203.
PubMed Abstract available

May 2025

BARBERIO B, Gracie DJ, Black CJ, Ford AC, et al
Network Meta-Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis.
Aliment Pharmacol Ther. 2025 May 23. doi: 10.1111/apt.70209.
PubMed Abstract available

OSTY M, Altwegg R, Serrero M, Benezech A, et al
Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study.
Aliment Pharmacol Ther. 2025 May 22. doi: 10.1111/apt.70199.
PubMed Abstract available

IRSHAD M, Irshad S
Letter: Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next-Generation Sequencing.
Aliment Pharmacol Ther. 2025 May 9. doi: 10.1111/apt.70152.
PubMed

SHINZAKI S, Takagi Y, Sato T
Editorial: Real-World Effectiveness of Mirikizumab in Ulcerative Colitis-A Valuable but Preliminary Glimpse. Authors' Reply.
Aliment Pharmacol Ther. 2025 May 5. doi: 10.1111/apt.70180.
PubMed

AINSWORTH MA, Frimor C
Editorial: Real-World Effectiveness of Mirikizumab in Ulcerative Colitis-A Valuable but Preliminary Glimpse.
Aliment Pharmacol Ther. 2025 May 5. doi: 10.1111/apt.70160.
PubMed

CASANOVA MJ, Rubin de Celix C, Riestra S, Lucendo AJ, et al
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.
Aliment Pharmacol Ther. 2025 May 2. doi: 10.1111/apt.70172.
PubMed Abstract available

CUSSAC C, Riviere P, Altwegg R, Caillo L, et al
Safety of Advanced Combination Treatment With Selective JAK1 Inhibitors and Biological Therapies in Inflammatory Bowel Diseases: A Real World Experience.
Aliment Pharmacol Ther. 2025;61:1692-1696.
PubMed Abstract available

TAN N, Zampogna C, Lynch K, Hannah N, et al
Patient Reported Outcomes in Primary Sclerosing Cholangitis: An Australian Perspective.
Aliment Pharmacol Ther. 2025;61:1612-1621.
PubMed Abstract available

April 2025

FITZPATRICK JA, Gibson PR, Halmos EP
Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers-A Conundrum That Continues. Authors' Reply.
Aliment Pharmacol Ther. 2025 Apr 29. doi: 10.1111/apt.70148.
PubMed

GOLD S, Haskey N, Raman M
Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers-A Conundrum That Continues.
Aliment Pharmacol Ther. 2025 Apr 29. doi: 10.1111/apt.70112.
PubMed

EBRAHIMI R, Ebrahimi F, Niess JH, Mahdi A, et al
Increased Risk of Cardiovascular Events After Coronary Interventions in Inflammatory Bowel Disease: A Nationwide Matched Cohort Study.
Aliment Pharmacol Ther. 2025 Apr 29. doi: 10.1111/apt.70162.
PubMed Abstract available

MCCURDY JD, Macdonald B, Rosenfeld G, Bessissow T, et al
Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply.
Aliment Pharmacol Ther. 2025 Apr 27. doi: 10.1111/apt.70170.
PubMed

ANAND E, Tozer P
Editorial: Seton Use in Perianal Fistulising Crohn's Disease.
Aliment Pharmacol Ther. 2025 Apr 27. doi: 10.1111/apt.70094.
PubMed

LIU D, Zhong B, Guo L
Letter: Re-Examining Seton Efficacy in Perianal Crohn's Disease-Considerations for Outcome Measurement and Clinical Interpretation.
Aliment Pharmacol Ther. 2025 Apr 25. doi: 10.1111/apt.70131.
PubMed

MCCURDY JD, Macdonald B, Rosenfeld G, Bessissow T, et al
Letter: Re-Examining Seton Efficacy in Perianal Crohn's Disease-Critical Considerations for Outcome Measurement and Clinical Interpretation. Authors' Reply.
Aliment Pharmacol Ther. 2025 Apr 25. doi: 10.1111/apt.70153.
PubMed

RICHARD N, Fumery M
Editorial: Real-World Evidence of Upadacitinib-An Effective Induction Therapy for Crohn's Disease? Authors' Reply.
Aliment Pharmacol Ther. 2025 Apr 14. doi: 10.1111/apt.70149.
PubMed

RAMOS-BELINCHON C, Plevris N
Editorial: Real-World Evidence of Upadacitinib-An Effective Induction Therapy for Crohn's Disease?
Aliment Pharmacol Ther. 2025 Apr 14. doi: 10.1111/apt.70113.
PubMed

KHUNSRIRAKSAKUL C, Ziegler O, Liu D, Kulaylat AS, et al
The Impact of Antispasmodic Use on Abdominal Pain and Opioid Use in Inflammatory Bowel Disease: A Population-Based Study.
Aliment Pharmacol Ther. 2025 Apr 11. doi: 10.1111/apt.70147.
PubMed Abstract available

TAKAGI Y, Sato T, Nishiguchi T, Nogami A, et al
Real-World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study.
Aliment Pharmacol Ther. 2025 Apr 9. doi: 10.1111/apt.70140.
PubMed Abstract available

MEYER A, Amiot A
Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis. Authors' Reply.
Aliment Pharmacol Ther. 2025 Apr 8. doi: 10.1111/apt.70138.
PubMed

ZHOU Z, Sun N, Liu Q
Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis.
Aliment Pharmacol Ther. 2025 Apr 8. doi: 10.1111/apt.70124.
PubMed

ALSAKARNEH S, Al Ta'ani O, Aburumman R, Mikhail I, et al
Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study.
Aliment Pharmacol Ther. 2025 Apr 7. doi: 10.1111/apt.70139.
PubMed Abstract available

DESAI A, Sehgal P
Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis-The Fat of the Matter: Authors' Reply.
Aliment Pharmacol Ther. 2025 Apr 3. doi: 10.1111/apt.70125.
PubMed

KURIAKOSE KUZHIYANJAL AJ, Limdi JK
Editorial: Obesity and Outcomes on Advanced Therapy in Ulcerative Colitis-The Fat of the Matter.
Aliment Pharmacol Ther. 2025 Apr 3. doi: 10.1111/apt.70097.
PubMed

MELTON S, Swaminathan A, Fitzpatrick J
Letter: Exclusive Enteral Nutrition in Ulcerative Colitis-The Path Ahead Needs Careful Consideration.
Aliment Pharmacol Ther. 2025 Apr 1. doi: 10.1111/apt.70091.
PubMed

XU ZC, Tan E, Garg M
Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression-Not as Simple as It Sounds.
Aliment Pharmacol Ther. 2025 Apr 1. doi: 10.1111/apt.70108.
PubMed

CHU MKW, Day AS, Broad L, Costello SP, et al
Letter: Exclusive Enteral Nutrition in Ulcerative Colitis-The Path Ahead Needs Careful Consideration. Authors' Reply.
Aliment Pharmacol Ther. 2025 Apr 1. doi: 10.1111/apt.70121.
PubMed

March 2025

MASSOURIDIS B, Swaminathan A
Editorial: Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow-Up.
Aliment Pharmacol Ther. 2025 Mar 22. doi: 10.1111/apt.70086.
PubMed

RIGGOTT C, Fairbrass KM, Gracie DJ, Ford AC, et al
Editorial: Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow-Up. Authors' Reply.
Aliment Pharmacol Ther. 2025 Mar 21. doi: 10.1111/apt.70100.
PubMed

JOUDAKI S, Oladipupo O, Carbery I, Lenti MV, et al
Meta-Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy.
Aliment Pharmacol Ther. 2025 Mar 20. doi: 10.1111/apt.70096.
PubMed Abstract available

MCCURDY J, Munir J, Parlow S, Sambhi G, et al
The Impact of Setons on Perianal Fistula Outcomes in Patients With Crohn's Disease Treated With Anti-TNF Therapy: A Multicentre Study.
Aliment Pharmacol Ther. 2025 Mar 18. doi: 10.1111/apt.70081.
PubMed Abstract available

HO FF, Wu IX, Chung VCH
Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply.
Aliment Pharmacol Ther. 2025 Mar 17. doi: 10.1111/apt.70093.
PubMed

HO AHY, Mak JWY
Editorial: Can We Prevent Inflammatory Bowel Disease?
Aliment Pharmacol Ther. 2025 Mar 17. doi: 10.1111/apt.70071.
PubMed

STRANGES V, Crowley E
Editorial: Upadacitinib-A Promising Induction Agent for Paediatric Crohn's Disease?
Aliment Pharmacol Ther. 2025 Mar 12. doi: 10.1111/apt.70076.
PubMed

HJALTE V, Myrelid P, Hjortswang H, Rejler M, et al
Substantial Reduction of Systemic Corticosteroid Use After Primary Ileocaecal Resection in Swedish Patients With Crohn's Disease: A Population-Based Cohort Study.
Aliment Pharmacol Ther. 2025 Mar 10. doi: 10.1111/apt.70069.
PubMed Abstract available

RIGGOTT C, Fairbrass KM, Gracie DJ, Ford AC, et al
Cumulative Impact of Clinical Disease Activity, Biochemical Activity and Psychological Health on the Natural History of Inflammatory Bowel Disease During 8 Years of Longitudinal Follow-Up.
Aliment Pharmacol Ther. 2025 Mar 9. doi: 10.1111/apt.70068.
PubMed Abstract available

RICHARD N, Amiot A, Seksik P, Altwegg R, et al
Effectiveness and Safety of Upadacitinib Induction Therapy for 223 Patients With Crohn's Disease: A GETAID Multicentre Cohort Study.
Aliment Pharmacol Ther. 2025 Mar 4. doi: 10.1111/apt.70073.
PubMed Abstract available

AMIOT A, Meyer A, Carbonnel F
Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply.
Aliment Pharmacol Ther. 2025 Mar 4. doi: 10.1111/apt.70070.
PubMed

MAK JWY
Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
Aliment Pharmacol Ther. 2025 Mar 4. doi: 10.1111/apt.70000.
PubMed

February 2025

CASSINOTTI A, Canova L
Editorial: Surveillance Colonoscopy for Detection of Neoplasia in Inflammatory Bowel Disease-Is Dye-Based Chromoendoscopy Always the Final Answer?
Aliment Pharmacol Ther. 2025 Feb 25. doi: 10.1111/apt.70027.
PubMed

SHEHAB M, Al-Hindawi A, Bessissow T
Editorial: Surveillance Colonoscopy for Detection of Neoplasia in Inflammatory Bowel Disease-Is Dye-Based Chromoendoscopy Always the Final Answer? Authors' Reply.
Aliment Pharmacol Ther. 2025 Feb 25. doi: 10.1111/apt.70057.
PubMed

KELM M, Flemming S
Letter in Response to: 'Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long-Term Outcomes: The ERIC Study'.
Aliment Pharmacol Ther. 2025 Feb 24. doi: 10.1111/apt.70013.
PubMed

GRELLIER N, Kirchgesner J, Seksik P
Letter: Early Ileal Resection in Crohn's Disease Is Not Associated With Severe Long-Term Outcomes: The ERIC Study: Authors' Reply.
Aliment Pharmacol Ther. 2025 Feb 24. doi: 10.1111/apt.70052.
PubMed

FITZPATRICK JA, Gibson PR, Taylor KM, Anderson EJ, et al
Clinical Trial: The Effects of Emulsifiers in the Food Supply on Disease Activity in Crohn's Disease: An Exploratory Double-Blinded Randomised Feeding Trial.
Aliment Pharmacol Ther. 2025 Feb 18. doi: 10.1111/apt.70041.
PubMed Abstract available

HO FF, Gao YY, Chen Y, Wang BH, et al
Association of Healthy Lifestyle Behaviours With Incident Inflammatory Bowel Disease: A Population-Based Prospective Cohort Study.
Aliment Pharmacol Ther. 2025 Feb 17. doi: 10.1111/apt.70031.
PubMed Abstract available

MENDOLARO M, Daperno M
Editorial: Endoscopic Activity is an Essential Tool for Patients' Management, Even in Mild Crohn's Disease.
Aliment Pharmacol Ther. 2025 Feb 15. doi: 10.1111/apt.70015.
PubMed

EGLINTON T
Editorial: Examining Perianal Fistulising Crohn's Disease Through the Lens of Wound Repair.
Aliment Pharmacol Ther. 2025 Feb 15. doi: 10.1111/apt.70001.
PubMed

COHEN S, Spencer EA, Dolinger MT, Suskind DL, et al
Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study.
Aliment Pharmacol Ther. 2025 Feb 8. doi: 10.1111/apt.70016.
PubMed Abstract available

WEINER BC
Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium.
Aliment Pharmacol Ther. 2025 Feb 4. doi: 10.1111/apt.18450.
PubMed

YE L, Cao Y, Fu Y, Tian C, et al
Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next-Generation Sequencing.
Aliment Pharmacol Ther. 2025 Feb 4. doi: 10.1111/apt.18522.
PubMed Abstract available

January 2025

BARTEL C, Minar P
Editorial: Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab.
Aliment Pharmacol Ther. 2025 Jan 31. doi: 10.1111/apt.18519.
PubMed

TEN BOKKEL HUININK S, Bak MTJ, Beelen EMJ, Erler NS, et al
The Impact of Postoperative Prophylactic Medication on Long-Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease.
Aliment Pharmacol Ther. 2025 Jan 24. doi: 10.1111/apt.18496.
PubMed Abstract available

QIAO L, Yang B
Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistulae: Authors' Reply.
Aliment Pharmacol Ther. 2025 Jan 24. doi: 10.1111/apt.18516.
PubMed

PARIAN AM, Schwartz DA
Editorial: Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistula.
Aliment Pharmacol Ther. 2025 Jan 24. doi: 10.1111/apt.18490.
PubMed

DESAI A, Sehgal P, Khataniar H, Lewis JD, et al
Obesity Is Associated With Worsened Outcomes in Patients With Ulcerative Colitis on Advanced Therapies: A Propensity Matched Cohort Study From the U.S.
Aliment Pharmacol Ther. 2025 Jan 22. doi: 10.1111/apt.18513.
PubMed Abstract available

SHEHAB M, Al-Hindawi A, Alrashed F, Murthy S, et al
Network Meta-Analysis: Comparison of Endoscopic Dysplasia Detection Technologies in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2025 Jan 18. doi: 10.1111/apt.18500.
PubMed Abstract available

CHU MKW, Day AS, Broad L, Costello SP, et al
Meta-Analysis: Exclusive Enteral Nutrition in Adults With Ulcerative Colitis.
Aliment Pharmacol Ther. 2025 Jan 16. doi: 10.1111/apt.18495.
PubMed Abstract available

MEYER A, Chan SSM, Touvier M, Julia C, et al
Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis.
Aliment Pharmacol Ther. 2025 Jan 16. doi: 10.1111/apt.18497.
PubMed Abstract available

STEIN R, Turner D, Hussey S, Kawasmi A, et al
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study.
Aliment Pharmacol Ther. 2025 Jan 15. doi: 10.1111/apt.18484.
PubMed Abstract available

KOMATSU M, Sagami S, Kobayashi T
Editorial: Leucine-Rich Alpha-2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease: Its Potential in Early-Stage Disease-Authors' Reply.
Aliment Pharmacol Ther. 2025 Jan 10. doi: 10.1111/apt.18493.
PubMed

MITCHELL A, Swaminathan A
Editorial: Leucine-Rich Alpha-2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease.
Aliment Pharmacol Ther. 2025 Jan 10. doi: 10.1111/apt.18463.
PubMed

WOELFEL S, Brand S
Editorial: Individualising JAK Inhibitor Selection for Patients With Ulcerative Colitis.
Aliment Pharmacol Ther. 2025 Jan 8. doi: 10.1111/apt.18476.
PubMed

AKIYAMA S, Fujii T
Editorial: Individualising JAK Inhibitor Selection for Patients With Ulcerative Colitis-Authors' Reply.
Aliment Pharmacol Ther. 2025 Jan 8. doi: 10.1111/apt.18489.
PubMed

MCFALLS C, Melia J
Editorial: Striving for Equitable Care in Ulcerative Colitis-Authors' Reply.
Aliment Pharmacol Ther. 2025 Jan 6. doi: 10.1111/apt.18454.
PubMed

BARNES EL
Editorial: Striving for Equitable Care in Ulcerative Colitis.
Aliment Pharmacol Ther. 2025 Jan 6. doi: 10.1111/apt.18423.
PubMed

MCCURDY JD, Hartley I, Behrenbruch C, Hart A, et al
Management of Perianal Fistulizing Crohn's Disease According to Principles of Wound Repair.
Aliment Pharmacol Ther. 2025 Jan 5. doi: 10.1111/apt.18466.
PubMed Abstract available

PERAZA J, Kaper ME, Bargas A, Kim I, et al
A Simple Endoscopic Score for Crohn's Disease (SES-CD) >/= 7 Predicts Disease Progression.
Aliment Pharmacol Ther. 2025 Jan 5. doi: 10.1111/apt.18492.
PubMed Abstract available

LEE T, Ding N, Chetwood JD
Editorial: Where to Start in Ulcerative Colitis?
Aliment Pharmacol Ther. 2025 Jan 2. doi: 10.1111/apt.18475.
PubMed

CAMMAROTA G, Laterza L, Bibbo S, Fusco W, et al
Review Article: Green Management of IBD-New Paradigms for an Eco-Friendly Approach.
Aliment Pharmacol Ther. 2025;61:65-74.
PubMed Abstract available

LEONG RW, Sakiris A, Arzivian A, Chetwood JD, et al
Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases.
Aliment Pharmacol Ther. 2025;61:132-144.
PubMed Abstract available

CARBERY I, Todd O, Hale M, Black CJ, et al
Meta-Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Diseases.
Aliment Pharmacol Ther. 2025;61:246-257.
PubMed Abstract available

December 2024

CARBERY I, Todd O, Selinger CP
Letter: Meta-Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease-Authors' Reply.
Aliment Pharmacol Ther. 2024 Dec 26. doi: 10.1111/apt.18464.
PubMed

DAI C, Huang YH, Jiang M
Letter: Meta-Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2024 Dec 26. doi: 10.1111/apt.18428.
PubMed

XIANG Y, Yang F, Yuan F, Gong Y, et al
Development and Validation of a Multimodal Machine Learning Model for Diagnosing and Assessing Risk of Crohn's Disease in Patients With Perianal Fistula.
Aliment Pharmacol Ther. 2024 Dec 18. doi: 10.1111/apt.18455.
PubMed Abstract available

HAYNESWORTH A, Yeh KH, Lee HH, Kirkpatrick M, et al
Long-Term Outcomes of an Infliximab-First Versus Vedolizumab-First Treatment Strategy in Biologic-Naive Patients With Ulcerative Colitis.
Aliment Pharmacol Ther. 2024 Dec 11. doi: 10.1111/apt.18441.
PubMed Abstract available

Correction to 'Stromal Vascular Fraction With Platelet-Rich Plasma Injection During Surgery is Feasible and Safe in Treatment-Refractory Perianal Fistulising Crohn's Disease: A Pilot Study'.
Aliment Pharmacol Ther. 2024 Dec 9. doi: 10.1111/apt.18388.
PubMed

MCCURDY JD, Wong SY
Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease-Effective or Hype?
Aliment Pharmacol Ther. 2024 Dec 6. doi: 10.1111/apt.18408.
PubMed

BACSUR P, Farkas K, Molnar T
Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease-Effective or Hype? Authors' Reply.
Aliment Pharmacol Ther. 2024 Dec 6. doi: 10.1111/apt.18427.
PubMed

KOMATSU M, Sagami S, Hojo A, Karashima R, et al
Leucine-Rich Alpha-2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease.
Aliment Pharmacol Ther. 2024 Dec 6. doi: 10.1111/apt.18430.
PubMed Abstract available

BACSUR P, Farkas K, Molnar T
Letter: Real-Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise-Authors' Reply.
Aliment Pharmacol Ther. 2024 Dec 5. doi: 10.1111/apt.18432.
PubMed

GAO W, Segal JP
Letter: Real-Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises the Importance of Appropriate Patient Selection and Centre Expertise.
Aliment Pharmacol Ther. 2024 Dec 5. doi: 10.1111/apt.18411.
PubMed

November 2024

MCFALLS C, Chaaban L, Melia J
Black Race is Associated with Decreased Exposure to Advanced Therapies and Worse Outcomes in Individuals with Ulcerative Colitis.
Aliment Pharmacol Ther. 2024 Nov 30. doi: 10.1111/apt.18405.
PubMed Abstract available

SWAMINATHAN A, Sparrow MP, Gearry RB
Letter: Extending the Measurement of Inflammatory Bowel Disease Severity to Include Patient Important Outcomes-Authors' Reply.
Aliment Pharmacol Ther. 2024 Nov 29. doi: 10.1111/apt.18421.
PubMed

FORBES AJ
Letter: Extending the Measurement of Inflammatory Bowel Disease Severity to Include Patient Important Outcomes.
Aliment Pharmacol Ther. 2024 Nov 29. doi: 10.1111/apt.18410.
PubMed

KHAN S, Munir A, Henna F, Fatima SM, et al
Letter: Critical Insights on a Nationwide Cohort Study of Inflammatory Bowel Disease, Histological Activity and Fracture Risk.
Aliment Pharmacol Ther. 2024 Nov 28. doi: 10.1111/apt.18336.
PubMed

ZHAO J, Xue E, Liu Z, Li X, et al
Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply.
Aliment Pharmacol Ther. 2024 Nov 27. doi: 10.1111/apt.18414.
PubMed

MENDOZA J, Irwin J
Editorial: Allostatic Load and Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2024 Nov 27. doi: 10.1111/apt.18325.
PubMed

AKIYAMA S, Shimizu H, Tamura A, Yokoyama K, et al
Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real-World Multicentre Study in Japan.
Aliment Pharmacol Ther. 2024 Nov 22. doi: 10.1111/apt.18406.
PubMed Abstract available

PAPAMICHAEL K, Cheifetz AS
Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
Aliment Pharmacol Ther. 2024 Nov 19. doi: 10.1111/apt.18360.
PubMed

HONG SN, Song JH, Kim SJ, Park YH, et al
Subcutaneous Infliximab Concentration Thresholds for Mucosal and Transmural Healing in Patients With Crohn's Disease.
Aliment Pharmacol Ther. 2024 Nov 18. doi: 10.1111/apt.18354.
PubMed Abstract available

SCHILDKRAUT T, Ding NJS, Chetwood JD
Letter: Bowel Preparation Quality in Patients With Crohn's Disease.
Aliment Pharmacol Ther. 2024 Nov 12. doi: 10.1111/apt.18350.
PubMed

SOLITANO V, Zou G, Jairath V
Letter: Bowel Preparation Quality in Patients With Crohn's Disease-Authors' Reply.
Aliment Pharmacol Ther. 2024 Nov 12. doi: 10.1111/apt.18394.
PubMed

GAO W, Segal JP
Understanding Factors Associated With Abdominal Pain in Ulcerative Colitis-No Surprises But the Usual Suspects Need Greater Attention.
Aliment Pharmacol Ther. 2024 Nov 6. doi: 10.1111/apt.18353.
PubMed

VAN GILS T, Tornblom H, Hreinsson JP, Jonefjall B, et al
Editorial: Understanding Factors Associated With Abdominal Pain in Ulcerative Colitis-No Surprises but the Usual Suspects Need Greater Attention. Authors' Reply.
Aliment Pharmacol Ther. 2024 Nov 6. doi: 10.1111/apt.18380.
PubMed

GEARRY RB, Seow CH, Subramanian S
Inflammatory bowel disease in 2024 and beyond.
Aliment Pharmacol Ther. 2024;60:1164-1165.
PubMed

CHAEMSUPAPHAN T, Leong RW, Vande Casteele N, Seow CH, et al
Review article: Optimisation of biologic (monoclonal antibody) therapeutic response in inflammatory bowel disease.
Aliment Pharmacol Ther. 2024;60:1234-1243.
PubMed Abstract available

SWAMINATHAN A, Day AS, Sparrow MP, Peyrin-Biroulet L, et al
Review article: Measuring disease severity in inflammatory bowel disease - Beyond treat to target.
Aliment Pharmacol Ther. 2024;60:1176-1199.
PubMed Abstract available

M NOOR N, Bourke A, Subramanian S
Review article: Novel therapies in inflammatory bowel disease - An update for clinicians.
Aliment Pharmacol Ther. 2024;60:1244-1260.
PubMed Abstract available

BRONZE S, Agrawal M, Colombel JF, Torres J, et al
Review article: Prevention of inflammatory bowel disease-The path forward.
Aliment Pharmacol Ther. 2024;60:1166-1175.
PubMed Abstract available

CLASSEN M, Schiller B, Dabritz J
Predicting complications in paediatric ulcerative colitis: A longitudinal multicentre cohort study.
Aliment Pharmacol Ther. 2024;60:1421-1434.
PubMed Abstract available

October 2024

WOELFEL S, Dutschler J, Junker D, Konig M, et al
XBB.1.5-Adapted COVID-19 mRNA Vaccines but Not Infections With Previous Omicron Variants Boost Neutralisation Against the SARS-CoV-2 JN.1 Variant in Patients With Inflammatory Bowel Disease.
Aliment Pharmacol Ther. 2024 Oct 29. doi: 10.1111/apt.18349.
PubMed Abstract available

BACSUR P, Shaham D, Serclova Z, Resal T, et al
Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real-Life Retrospective Multicentre Cohort Study.
Aliment Pharmacol Ther. 2024 Oct 28. doi: 10.1111/apt.18359.
PubMed Abstract available

MARILD K, Lerchova T, Ostensson M, Imberg H, et al
Early-Life Infections, Antibiotics and Later Risk of Childhood and Early Adult-Onset Inflammatory Bowel Disease: Pooled Analysis of Two Scandinavian Birth Cohorts.
Aliment Pharmacol Ther. 2024 Oct 25. doi: 10.1111/apt.18358.
PubMed Abstract available

Correction to 'A Personalised Algorithm Predicting the Risk of Intravenous Corticosteroid Failure in Acute Ulcerative Colitis'.
Aliment Pharmacol Ther. 2024 Oct 24. doi: 10.1111/apt.18357.
PubMed

VAN GILS T, Tornblom H, Hreinsson JP, Jonefjall B, et al
Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study.
Aliment Pharmacol Ther. 2024 Oct 23. doi: 10.1111/apt.18344.
PubMed Abstract available

CLASSEN M, Schiller B, Dabritz J
Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis-Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply.
Aliment Pharmacol Ther. 2024 Oct 18. doi: 10.1111/apt.18348.
PubMed

LUO A
Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis-Addressing Socioeconomic, Environmental and Clinical Factors.
Aliment Pharmacol Ther. 2024 Oct 18. doi: 10.1111/apt.18327.
PubMed

BOGATIC D, Bryant RV
Letter: Gut microbiota-An overlooked therapeutic target in the prevention of post-operative recurrence of Crohn's disease.
Aliment Pharmacol Ther. 2024 Oct 17. doi: 10.1111/apt.18258.
PubMed

KHARAL M, Shahbaz MH, Nadeem MS, Shahbaz S, et al
Letter: Allostatic load-A potential key in the development of inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Oct 17. doi: 10.1111/apt.18270.
PubMed

DULAI PS, Bonner LB, Sadler C, Raffals LE, et al
Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC Consortium.
Aliment Pharmacol Ther. 2024 Oct 15. doi: 10.1111/apt.18326.
PubMed Abstract available

MOCCI G, Tursi A
Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis-Where we are now.
Aliment Pharmacol Ther. 2024 Oct 7. doi: 10.1111/apt.18272.
PubMed

PILLAY L, Christensen B
Editorial: Re-evaluating early surgery in Ileocaecal Crohn's disease.
Aliment Pharmacol Ther. 2024 Oct 7. doi: 10.1111/apt.18290.
PubMed

GRELLIER N, Kirchgesner J, Seksik P
Editorial: Re-Evaluating Early Surgery in Ileocaecal Crohn's Disease. Author's Reply.
Aliment Pharmacol Ther. 2024 Oct 7. doi: 10.1111/apt.18320.
PubMed

CHAPARRO M, Gisbert JP
Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis-Where We Are Now in Real Life. Authors' Reply.
Aliment Pharmacol Ther. 2024 Oct 7. doi: 10.1111/apt.18316.
PubMed

ZHAO J, Xue E, Liu Z, Li X, et al
Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease-Need More Evidence. Authors' Reply.
Aliment Pharmacol Ther. 2024 Oct 5. doi: 10.1111/apt.18303.
PubMed

XU L, Guan C, Zhao L, Xu Y, et al
Letter: Allostatic load and adverse prognosis in inflammatory bowel disease-Need more evidence.
Aliment Pharmacol Ther. 2024 Oct 5. doi: 10.1111/apt.18249.
PubMed

ESTEVINHO MM, Sousa-Pinto B, Moreira PL, Solitano V, et al
Network Meta-Analysis: Histologic and Histo-Endoscopic Improvement and Remission With Advanced Therapy in Ulcerative Colitis.
Aliment Pharmacol Ther. 2024 Oct 5. doi: 10.1111/apt.18315.
PubMed Abstract available

RIGGOTT C, Ford AC, Gracie DJ
Review article: The role of the gut-brain axis in inflammatory bowel disease and its therapeutic implications.
Aliment Pharmacol Ther. 2024 Oct 5. doi: 10.1111/apt.18192.
PubMed Abstract available

GREEN Z, Ashton JJ
Editorial: Prediction in Inflammatory Bowel Disease-Do the Answers Lie in Big Clinical Data?
Aliment Pharmacol Ther. 2024 Oct 5. doi: 10.1111/apt.18301.
PubMed

MOLINARO A, de Ridder L
Editorial: Distinct Challenges of Paediatric From Adult-Onset Inflammatory Bowel Disease, Implications of Aggressive Disease Phenotypes and Early Biologic Therapy in Children.
Aliment Pharmacol Ther. 2024 Oct 4. doi: 10.1111/apt.18299.
PubMed

GRANOT M, Weiss B, Haberman Y
Editorial: Distinct Challenges of Paediatric From Adult-Onset Inflammatory Bowel Disease, Implications of Aggressive Disease Phenotypes and Early Biologic Therapy in Children-Authors' Reply.
Aliment Pharmacol Ther. 2024 Oct 4. doi: 10.1111/apt.18310.
PubMed

September 2024

ZAMANI M, Alizadeh-Tabari S, Murad MH, Singh S, et al
Meta-analysis: Risk of lymphoma in patients with inflammatory bowel disease in population-based cohort studies.
Aliment Pharmacol Ther. 2024 Sep 23. doi: 10.1111/apt.18277.
PubMed Abstract available

MARILD K, Soderling J, Axelrad J, Halfvarson J, et al
A nationwide cohort study of inflammatory bowel disease, histological activity and fracture risk.
Aliment Pharmacol Ther. 2024 Sep 23. doi: 10.1111/apt.18275.
PubMed Abstract available

SOLITANO V, Ma C, Jairath V
Editorial: Advancing care in Crohn's disease-Time to standardise bowel preparation scales. Authors' reply.
Aliment Pharmacol Ther. 2024 Sep 19. doi: 10.1111/apt.18288.
PubMed

SHEHAB M, Bessissow T
Editorial: Advancing care in Crohn's disease-Time to standardise bowel preparation scales.
Aliment Pharmacol Ther. 2024 Sep 19. doi: 10.1111/apt.18269.
PubMed

CHAPARRO M, Hermida S, Acosta D, Fernandez-Clotet A, et al
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.
Aliment Pharmacol Ther. 2024 Sep 17. doi: 10.1111/apt.18230.
PubMed Abstract available

GRANOT M, Kopylov U, Loberman-Nachum N, Krauthammer A, et al
Differences in disease characteristics and treatment exposures between paediatric and adult-onset inflammatory bowel disease using a registry-based cohort.
Aliment Pharmacol Ther. 2024 Sep 10. doi: 10.1111/apt.18264.
PubMed Abstract available

GRELLIER N, Kirchgesner J, Uzzan M, McLellan P, et al
Early ileal resection in Crohn's disease is not associated with severe long-term outcomes: The ERIC study.
Aliment Pharmacol Ther. 2024 Sep 5. doi: 10.1111/apt.18247.
PubMed Abstract available

PAL P, Mateen MA, Pooja K, Marri UK, et al
Leveraging existing mid-end ultrasound machine for point-of-care intestinal ultrasound in low-resource settings: Prospective, real-world impact on clinical decision-making.
Aliment Pharmacol Ther. 2024;60:633-647.
PubMed Abstract available

FERREIRO-IGLESIAS R, Porto Silva S, Marin S, Casanova MJ, et al
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry.
Aliment Pharmacol Ther. 2024;60:604-612.
PubMed Abstract available

LING LUNDSTROM M, Peterson C, Hedin CRH, Bergemalm D, et al
Faecal biomarkers for diagnosis and prediction of disease course in treatment-naive patients with IBD.
Aliment Pharmacol Ther. 2024;60:765-777.
PubMed Abstract available

August 2024

JIANG F, Yang W, Cao Y, Cao X, et al
The contribution of dietary advanced glycation end-products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study.
Aliment Pharmacol Ther. 2024 Aug 23. doi: 10.1111/apt.18218.
PubMed Abstract available

ZHAO J, Xue E, Zhou S, Zhang M, et al
Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Aug 21. doi: 10.1111/apt.18217.
PubMed Abstract available

GIBSON PR, Yao CK, Halmos EP
Review article: Evidence-based dietary management of inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Aug 20. doi: 10.1111/apt.18214.
PubMed Abstract available

SOLITANO V, Siegel CA, Korzenik JR, Maratt JK, et al
Performance of bowel preparation quality scales in patients with Crohn's disease.
Aliment Pharmacol Ther. 2024 Aug 11. doi: 10.1111/apt.18210.
PubMed Abstract available

CROFT A, Okano S, Hartel G, Lord A, et al
A personalised algorithm predicting the risk of intravenous corticosteroid failure in acute ulcerative colitis.
Aliment Pharmacol Ther. 2024 Aug 7. doi: 10.1111/apt.18190.
PubMed Abstract available

MATHIAS RM, Bryant RV
Letter: Light in the lumen-The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Aug 6. doi: 10.1111/apt.18161.
PubMed

MUJAGIC Z, Aliu A, Bosch DHCA, Keszthelyi D, et al
Letter: Light in the lumen-The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease. Authors' reply.
Aliment Pharmacol Ther. 2024 Aug 6. doi: 10.1111/apt.18196.
PubMed

SELINGER CP, Baillie S, Pollok R
Letter: Addressing opioid exposure and associated harms in patients with IBD.
Aliment Pharmacol Ther. 2024;60:423-424.
PubMed

CHATTERJEE A, Yadav AI, Sekar A, Singh H, et al
Letter: Extreme diagnostic delay due to misdiagnosis of gastrointestinal tuberculosis later diagnosed as postoperative Crohn's disease.
Aliment Pharmacol Ther. 2024;60:537-539.
PubMed

CROUWEL F, Simsek M, de Boer MA, van Asseldonk DP, et al
Multicentre study and systematic review: Allopurinol exposure during pregnancy.
Aliment Pharmacol Ther. 2024;60:503-518.
PubMed Abstract available

July 2024

FEAGAN BG, Matsuoka K, Rogler G, Laharie D, et al
Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study.
Aliment Pharmacol Ther. 2024 Jul 31. doi: 10.1111/apt.18158.
PubMed Abstract available

SEQUIER L, Caron B, Loeuille D, Honap S, et al
Systematic review: Methotrexate-A poorly understood and underused medication in inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Jul 30. doi: 10.1111/apt.18194.
PubMed Abstract available

LAN Q, Guo L, Xiong Z
Letter: Critical appraisal of biologic therapy in management of early ulcerative colitis-Addressing study limitations and the role of psychological resilience.
Aliment Pharmacol Ther. 2024 Jul 28. doi: 10.1111/apt.18156.
PubMed

STRANDE V, Hoivik ML, Kristensen VA
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management-Addressing study limitations and the role of psychological resilience-Authors' reply.
Aliment Pharmacol Ther. 2024 Jul 28. doi: 10.1111/apt.18187.
PubMed

SCHREIBER S, Cross RK, Panaccione R, D'Haens G, et al
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease.
Aliment Pharmacol Ther. 2024 Jul 25. doi: 10.1111/apt.18184.
PubMed Abstract available

ARVANITAKIS K, Germanidis G
Editorial: GLP-1 receptor agonists in inflammatory bowel disease-Is it time?
Aliment Pharmacol Ther. 2024 Jul 21. doi: 10.1111/apt.18152.
PubMed

BOGATIC D, Bryant RV
Letter: Microbial manipulation for primary sclerosing cholangitis-associated inflammatory bowel disease-hope on the horizon.
Aliment Pharmacol Ther. 2024 Jul 16. doi: 10.1111/apt.18098.
PubMed

WEWER MD, Nordestgaard RLM, Malham M, Wewer V, et al
Editorial: Treatments of inflammatory bowel disease across age-spectrum-Are they the same? Authors' reply.
Aliment Pharmacol Ther. 2024 Jul 8. doi: 10.1111/apt.18163.
PubMed

HO AHY, Mak JWY
Editorial: Treatments for inflammatory bowel disease across the age spectrum-Are they the same?
Aliment Pharmacol Ther. 2024 Jul 8. doi: 10.1111/apt.18143.
PubMed

June 2024

DESAI A, Petrov J, Hashash JG, Patel H, et al
Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Jun 27. doi: 10.1111/apt.18138.
PubMed Abstract available

RAO V, Chen G, Koh E, Segal JP, et al
Letter: Persisting with persistence-Caution as an outcome measure in inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Jun 24. doi: 10.1111/apt.18114.
PubMed

YIU TH, Ko Y, Pudipeddi A, Natale P, et al
Letter: Persisting with persistence-A caution as an outcome measure in inflammatory bowel disease: Authors' reply.
Aliment Pharmacol Ther. 2024 Jun 24. doi: 10.1111/apt.18136.
PubMed

BAK MTJ, Demers K, Hammoudi N, Allez M, et al
Systematic review: Patient-related, microbial, surgical, and histopathological risk factors for endoscopic post-operative recurrence in patients with Crohn's disease.
Aliment Pharmacol Ther. 2024 Jun 17. doi: 10.1111/apt.18040.
PubMed Abstract available

CHHIBBA T
Editorial: Surgery to reduce opioid use in Crohn's disease: Does a classic solution address a newer problem?
Aliment Pharmacol Ther. 2024 Jun 14. doi: 10.1111/apt.18051.
PubMed

SEO J, Kim S, Hong SW, Hwang SW, et al
Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study.
Aliment Pharmacol Ther. 2024 Jun 12. doi: 10.1111/apt.18102.
PubMed Abstract available

ATTAUABI M, Steenholdt C, Poulsen A, Gubatan J, et al
Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease.
Aliment Pharmacol Ther. 2024 Jun 11. doi: 10.1111/apt.18110.
PubMed Abstract available

NORDESTGAARD RLM, Wewer MD, Malham M, Wewer V, et al
Treatment of inflammatory bowel disease with steroid-sparing medications is age-dependent - Results from a Danish nationwide cohort study, 2000-2018.
Aliment Pharmacol Ther. 2024 Jun 10. doi: 10.1111/apt.18106.
PubMed Abstract available

FUKUDA T, Yamazaki H, Matsuoka K
Editorial: Mucosal healing with steroids-Once upon a time in ulcerative colitis. Authors' reply.
Aliment Pharmacol Ther. 2024 Jun 9. doi: 10.1111/apt.18111.
PubMed

BARREIRO-DE ACOSTA M, Rodriguez-Lago I
Editorial: Mucosal healing with steroids: Once upon a time in ulcerative colitis.
Aliment Pharmacol Ther. 2024 Jun 9. doi: 10.1111/apt.18094.
PubMed

GARCIA MJ, Gisbert JP, Chaparro M
Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions-Authors' reply.
Aliment Pharmacol Ther. 2024 Jun 6. doi: 10.1111/apt.18104.
PubMed

STRANDE V, Lund C, Hagen M, Bengtson MB, et al
Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort.
Aliment Pharmacol Ther. 2024 Jun 4. doi: 10.1111/apt.18097.
PubMed Abstract available

CHETWOOD JD, Ding NS
Letter: Third-line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions.
Aliment Pharmacol Ther. 2024 Jun 3. doi: 10.1111/apt.18056.
PubMed

SONG S, Lv J, Li L, Pang Y, et al
Editorial: Exploring the influence of diet on later-onset ulcerative colitis-Are eggs and spicy foods the key factors in Asia? Authors' reply.
Aliment Pharmacol Ther. 2024;59:1453-1454.
PubMed

ALIU A, Bosch DHCA, Keszthelyi D, Ardabili AR, et al
Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD-Authors' reply.
Aliment Pharmacol Ther. 2024;59:1646-1647.
PubMed

LEONG RW, Jairath V, Ma C
Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD.
Aliment Pharmacol Ther. 2024;59:1644-1645.
PubMed

BEATON D, Sharp L, Lu L, Trudgill N, et al
Diagnostic yield from symptomatic lower gastrointestinal endoscopy in the UK: A British Society of Gastroenterology analysis using data from the National Endoscopy Database.
Aliment Pharmacol Ther. 2024;59:1589-1603.
PubMed Abstract available

May 2024

DUTT K, Vasudevan A
Editorial: Exclusive enteral nutrition: Positioning in the ever-growing landscape of inflammatory bowel disease therapy.
Aliment Pharmacol Ther. 2024 May 23. doi: 10.1111/apt.18055.
PubMed

ALAHMAD M, Quraishi MN, Khan SW, Omar NM, et al
Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease.
Aliment Pharmacol Ther. 2024 May 23. doi: 10.1111/apt.18049.
PubMed

YIU TH, Ko Y, Pudipeddi A, Natale P, et al
Letter: Early real-world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease-Authors' reply.
Aliment Pharmacol Ther. 2024 May 23. doi: 10.1111/apt.18057.
PubMed

VUIJK SA, de Ridder L
Editorial: Infliximab induction therapy in paediatric Crohn's disease: A cost-effective strategy? Authors' reply.
Aliment Pharmacol Ther. 2024 May 21. doi: 10.1111/apt.18053.
PubMed

CHANCHLANI N, Russell RK
Editorial: Infliximab induction therapy in pediatric Crohn's disease-A cost-effective strategy?
Aliment Pharmacol Ther. 2024 May 21. doi: 10.1111/apt.18033.
PubMed

PLOTKIN L, Buchuk R, Lujan R, Focht G, et al
Enteral nutrition compared with corticosteroids in children with Crohn's disease: A long-term nationwide study from the epi-IIRN.
Aliment Pharmacol Ther. 2024 May 14. doi: 10.1111/apt.18028.
PubMed Abstract available

NEDUMANNIL L, Mohamedrashed M, Bohra A, Sood S, et al
Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease.
Aliment Pharmacol Ther. 2024;59:1162-1163.
PubMed

BARTH I, Stevens CL, Strokap CJ, Campmans-Kuijpers MJE, et al
Letter: Diet-microbiome interactions in inflammatory bowel disease-Navigating towards individualised dietary strategies.
Aliment Pharmacol Ther. 2024;59:1154-1155.
PubMed

THWAITES PA, Gibson PR
Letter: The emerging role of novel capsule endoscopy systems in gastroenterology with specific reference to small bowel Crohn's disease. Authors' reply.
Aliment Pharmacol Ther. 2024;59:1164-1165.
PubMed

SEIDELIN JB
Editorial: Time to address quality of life in our IBD treatment-IBD nurse intervention as a key part of multimodal IBD management.
Aliment Pharmacol Ther. 2024;59:1152-1153.
PubMed

GARCIA MJ, Gisbert JP, Chaparro M
Editorial: Sequencing rescue therapy for acute severe ulcerative colitis-Ready for revision? Authors' reply.
Aliment Pharmacol Ther. 2024;59:1298-1299.
PubMed

DERIKX LAAP, Hoentjen F
Editorial: Sequencing rescue therapy for acute severe ulcerative colitis-Ready for revision?
Aliment Pharmacol Ther. 2024;59:1296-1297.
PubMed

SHAH A, Holtmann G
Editorial: Is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis-associated inflammatory bowel disease?
Aliment Pharmacol Ther. 2024;59:1290-1291.
PubMed

NORGARD BM, Thorarinsson CT, Zegers FD, Kjeldsen J, et al
The use of opioids nine months after surgery for Crohn's disease - a nationwide cohort study.
Aliment Pharmacol Ther. 2024 May 1. doi: 10.1111/apt.18014.
PubMed Abstract available

April 2024

SONG S, Wu Z, Lv J, Yu C, et al
Dietary factors and patterns in relation to risk of later-onset ulcerative colitis in Chinese: A prospective study of 0.5 million people.
Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.17963.
PubMed Abstract available

FUKUDA T, Yamazaki H, Miyatani Y, Sawada T, et al
Recent steroid use and the relapse risk in ulcerative colitis patients with endoscopic healing.
Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.18013.
PubMed Abstract available

YIU TH, Ko Y, Pudipeddi A, Natale P, et al
Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.18006.
PubMed Abstract available

FERNANDEZ-CLOTET A, Ordas I, Masamunt MC, Caballol B, et al
Magnetic resonance enterography findings 46 weeks after initiation of biological therapy predict long-term adverse outcomes in Crohn's disease.
Aliment Pharmacol Ther. 2024 Apr 23. doi: 10.1111/apt.17968.
PubMed Abstract available

VUIJK SA, Jongsma MME, Hoeven BM, Cozijnsen MA, et al
Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.18000.
PubMed Abstract available

URQUHART SA, Fletcher JG, Bruining DH
Editorial: Foretelling the future-Emerging role of magnetic resonance enterography as a prognostic tool in Crohn's disease.
Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17991.
PubMed

OKABAYASHI S, Kobayashi T
Editorial: Exploring the influence of diet on later-onset ulcerative colitis-Are eggs and spicy foods the key factors in Asia?
Aliment Pharmacol Ther. 2024 Apr 21. doi: 10.1111/apt.17983.
PubMed

ARATARI A, Scribano ML, Pugliese D, Baccolini V, et al
Crohn's disease after surgery: Changes in post-operative management strategies over time and their impact on long-term re-operation rate-A retrospective multicentre real-world study.
Aliment Pharmacol Ther. 2024 Apr 14. doi: 10.1111/apt.18001.
PubMed Abstract available

KIM K, Park JJ, Yoon H, Lee J, et al
Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study.
Aliment Pharmacol Ther. 2024 Apr 14. doi: 10.1111/apt.17989.
PubMed Abstract available

ALIU A, Bosch DHCA, Keszthelyi D, Rezazadeh Ardabili A, et al
Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission.
Aliment Pharmacol Ther. 2024 Apr 8. doi: 10.1111/apt.17988.
PubMed Abstract available

VASUDEVAN A, Con D, van Langenberg DR
Letter: Thioguanine, an under-utilised option in inflammatory bowel disease? Authors' reply.
Aliment Pharmacol Ther. 2024;59:1011.
PubMed

ASONUMA K, Sagami S, Kobayashi T
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights.
Aliment Pharmacol Ther. 2024;59:1005-1006.
PubMed

CHETWOOD JD, Paramsothy S, Leong RW
Letter: Thioguanine, an underutilised option in inflammatory bowel disease?
Aliment Pharmacol Ther. 2024;59:1009-1010.
PubMed

March 2024

AKIYAMA S, Yokoyama K, Yagi S, Shinzaki S, et al
Efficacy and safety of filgotinib for ulcerative colitis: A real-world multicenter retrospective study in Japan.
Aliment Pharmacol Ther. 2024 Mar 17. doi: 10.1111/apt.17961.
PubMed Abstract available

RICCIUTO A, Liu K, El-Matary W, Amin M, et al
Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): A matched analysis from the Paediatric PSC Consortium.
Aliment Pharmacol Ther. 2024 Mar 10. doi: 10.1111/apt.17936.
PubMed Abstract available

GARCIA MJ, Riestra S, Amiot A, Julsgaard M, et al
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).
Aliment Pharmacol Ther. 2024 Mar 6. doi: 10.1111/apt.17938.
PubMed Abstract available

LU C, Rosentreter R, Delisle M, White M, et al
Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound.
Aliment Pharmacol Ther. 2024 Mar 4. doi: 10.1111/apt.17918.
PubMed Abstract available

GONCZI L, Lakatos L, Ilias A, Lakatos PL, et al
Editorial: The prevalence and outcomes of perianal Crohn's disease across the treatment eras-Authors' reply.
Aliment Pharmacol Ther. 2024;59:715-716.
PubMed

LENFANT M, Verstockt B, Sabino J, Vermeire S, et al
Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply.
Aliment Pharmacol Ther. 2024;59:723-724.
PubMed

LAHARIE D
Letter: Should ulcerative colitis be monitored more or less invasively?
Aliment Pharmacol Ther. 2024;59:721-722.
PubMed

TASSONE D, Hartley I, Ding NS
Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras.
Aliment Pharmacol Ther. 2024;59:713-714.
PubMed

VAN LIERE ELSA, de Boer NKH
Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease.
Aliment Pharmacol Ther. 2024;59:792-793.
PubMed

VASUDEVAN A, Con D, van Langenberg DR
Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease-authors' reply.
Aliment Pharmacol Ther. 2024;59:794.
PubMed

BOKEMEYER B, Plachta-Danielzik S, Steiner IM, Pohlschneider D, et al
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBD(BIO-ASSIST) study).
Aliment Pharmacol Ther. 2024 Mar 1. doi: 10.1111/apt.17926.
PubMed Abstract available

February 2024

ERIKSSON C, Sun J, Bryder M, Broms G, et al
Impact of inflammatory bowel disease on the risk of acute coronary syndrome: A Swedish Nationwide Cohort Study.
Aliment Pharmacol Ther. 2024 Feb 29. doi: 10.1111/apt.17932.
PubMed Abstract available

ZAMANI M, Alizadeh-Tabari S, Murad MH, Ananthakrishnan AN, et al
Meta-analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2024 Feb 19. doi: 10.1111/apt.17919.
PubMed Abstract available

SAGAMI S, Kobayashi T
Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety.
Aliment Pharmacol Ther. 2024;59:579-580.
PubMed

PANACCIONE R
Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety. Author's reply.
Aliment Pharmacol Ther. 2024;59:581-582.
PubMed

VASUDEVAN A, Con D, De Cruz P, Sparrow MP, et al
Clinical trial: Combination allopurinol-thiopurine versus standard thiopurine in patients with IBD escalating to immunomodulators (the DECIDER study).
Aliment Pharmacol Ther. 2024;59:504-514.
PubMed Abstract available

January 2024

CON D, Srinivasan A
Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-it depends on how you use the drug.
Aliment Pharmacol Ther. 2024;59:140-141.
PubMed

VAN DE MEEBERG MM, Fidder HH, de Jonge R, Bouma G, et al
Editorial: Monitoring methotrexate polyglutamates in Crohn's disease-Authors' reply.
Aliment Pharmacol Ther. 2024;59:120-121.
PubMed

BARCLAY ML, Stamp LK
Editorial: Monitoring methotrexate polyglutamates in Crohn's disease.
Aliment Pharmacol Ther. 2024;59:118-119.
PubMed

PRAY C, Narula N
Editorial: Moving towards prognostic endoscopic scoring in IBD.
Aliment Pharmacol Ther. 2024;59:132-133.
PubMed

December 2023

GONCZI L, Lakatos L, Golovics PA, Angyal D, et al
Burden of perianal disease in Crohn's disease: Accelerating medical therapy and high rates of perianal surgery over the last four decades - Results from a population-based study over four decades.
Aliment Pharmacol Ther. 2023 Dec 19. doi: 10.1111/apt.17836.
PubMed Abstract available

MEYER A, Dong C, Chan SSM, Touvier M, et al
Dietary index based on the Food Standards Agency nutrient profiling system and risk of Crohn's disease and ulcerative colitis.
Aliment Pharmacol Ther. 2023 Dec 15. doi: 10.1111/apt.17835.
PubMed Abstract available

DESAI A, Regueiro M, Kochhar GS
Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis-Authors' reply.
Aliment Pharmacol Ther. 2023;58.
PubMed

SOHN J
Editorial: Unravelling the relationship between periodontal disease and inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;58.
PubMed

REZAZADEH ARDABILI A, Janssen L, Mujagic Z
Letter: Abdominal pain in patients with inflammatory bowel disease in remission - A look beyond psychosocial factors. Authors' reply.
Aliment Pharmacol Ther. 2023;58.
PubMed

CHANG HC, Gau SY
Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis.
Aliment Pharmacol Ther. 2023;58.
PubMed

BASSOTTI G, Villanacci V, Maconi G
Letter: Abdominal pain in inflammatory bowel disease patients in remission-A look beyond psychosocial factors.
Aliment Pharmacol Ther. 2023;58.
PubMed

November 2023

BUISSON A, Nachury M, Bazoge M, Yzet C, et al
Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study.
Aliment Pharmacol Ther. 2023 Nov 30. doi: 10.1111/apt.17822.
PubMed Abstract available

PEYRIN-BIROULET L, Vermeire S, D'Haens G, Panes J, et al
Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long-term extension period of STARDUST.
Aliment Pharmacol Ther. 2023 Nov 30. doi: 10.1111/apt.17751.
PubMed Abstract available

PANACCIONE R, Danese S, Zhou W, Klaff J, et al
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
Aliment Pharmacol Ther. 2023 Nov 27. doi: 10.1111/apt.17816.
PubMed Abstract available

BOKEMEYER B, Plachta-Danielzik S
Letter: Comparing first-line infliximab and vedolizumab for ulcerative colitis-It depends on how you use the drug. Authors' reply.
Aliment Pharmacol Ther. 2023 Nov 4. doi: 10.1111/apt.17796.
PubMed

KELLER JJ, Terveer EM
Editorial: Continuous monitoring to improve outcome of treatment-the next step towards safe and effective faecal microbiota transplantation.
Aliment Pharmacol Ther. 2023;58:946-947.
PubMed

DAN L, Wang X, Chen J
Editorial: Unravelling the fibres-low dietary fibre may lower risk of developing IBD. Authors' reply.
Aliment Pharmacol Ther. 2023;58:940-941.
PubMed

LOPES EW, Khalili H
Editorial: Unravelling the fibres-low dietary fibre may lower risk of developing IBD.
Aliment Pharmacol Ther. 2023;58:938-939.
PubMed

October 2023

SPARTZ EJ, DeDecker LC, Fansiwala KM, Noorian S, et al
Recent trends and risk factors associated with Clostridioides difficile infections in hospitalized patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Oct 24. doi: 10.1111/apt.17777.
PubMed Abstract available

LENFANT M, Verstockt B, Sabino J, Vermeire S, et al
The assessment of segmental healing by the Modified Mayo Endoscopic Score (MMES) complements the prediction of long-term clinical outcomes in patients with ulcerative colitis.
Aliment Pharmacol Ther. 2023 Oct 16. doi: 10.1111/apt.17753.
PubMed Abstract available

DAJTI E, Frazzoni L, Iascone V, Secco M, et al
Systematic review with meta-analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
Aliment Pharmacol Ther. 2023 Oct 12. doi: 10.1111/apt.17754.
PubMed Abstract available

KAYAL M, Meringer H, Martin L, Colombel JF, et al
Scores used to predict outcomes in acute severe ulcerative colitis: A systematic review.
Aliment Pharmacol Ther. 2023 Oct 11. doi: 10.1111/apt.17731.
PubMed Abstract available

RIGGOTT C, Fairbrass KM, Black CJ, Gracie DJ, et al
Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study.
Aliment Pharmacol Ther. 2023 Oct 4. doi: 10.1111/apt.17735.
PubMed Abstract available

WILLIAMS KM, Challa PK, Lopes EW, Burke KE, et al
Periodontal disease is not associated with risk of inflammatory bowel disease: Results from two prospective cohort studies in the US.
Aliment Pharmacol Ther. 2023 Oct 2. doi: 10.1111/apt.17732.
PubMed Abstract available

TASSONE D, Hartley I, Ding NS
Letter: Muscle thickness measurement using ultrasound-A step closer to the use of body composition analysis in the management of inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;58:729-730.
PubMed

ANDREW B, Zhou A, Trinh S, Srinivasan A, et al
Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed.
Aliment Pharmacol Ther. 2023;58:838-839.
PubMed

OH SJ, Kim HJ, Lee CK
Letter: Antibiotics in gut dysbiosis and development of inflammatory bowel disease-More thought is needed-Authors' reply.
Aliment Pharmacol Ther. 2023;58:840-841.
PubMed

ARULJOTHY A, Singh S, Narula N, Moran GW, et al
Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
Aliment Pharmacol Ther. 2023;58:740-762.
PubMed Abstract available

REZAZADEH ARDABILI A, Van Bodegraven AA
Editorial: IBD cost evolution - transitioning from compensating lost productivity to escalating medication expenses.
Aliment Pharmacol Ther. 2023;58:832-833.
PubMed

September 2023

VAN DE MEEBERG MM, Fidder HH, Oldenburg B, Sundaresan J, et al
Therapeutic drug monitoring of methotrexate in patients with Crohn's disease.
Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17719.
PubMed Abstract available

FAQERAH N, Walker D, Gerasimidis K
Review article: The complex interplay between diet and Escherichia coli in inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Sep 28. doi: 10.1111/apt.17720.
PubMed Abstract available

JANSSEN LM, Rezazadeh Ardabili A, Romberg-Camps MJL, Winkens B, et al
Abdominal pain in patients with inflammatory bowel disease in remission: A prospective study on contributing factors.
Aliment Pharmacol Ther. 2023 Sep 19. doi: 10.1111/apt.17718.
PubMed Abstract available

SCHREIBER S, Rogler G, Watanabe M, Vermeire S, et al
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE.
Aliment Pharmacol Ther. 2023 Sep 18. doi: 10.1111/apt.17674.
PubMed Abstract available

ANDREW B, Srinivasan A, Zhou A, Vasudevan A, et al
Letter: Elderly onset inflammatory bowel disease-Treat to target approach is still warranted.
Aliment Pharmacol Ther. 2023;58:556-557.
PubMed

YAMAMOTO T
Editorial: Is vedolizumab the preferred biologic therapy for biologic-naive patients with ulcerative colitis?
Aliment Pharmacol Ther. 2023;58:546-547.
PubMed

DIGNASS A, Rath S, Kleindienst T, Stallmach A, et al
Review article: Translating STRIDE-II into clinical reality - Opportunities and challenges.
Aliment Pharmacol Ther. 2023;58:492-502.
PubMed Abstract available

WU X, Yang Y
Letter: Chinese herbal medicine Curcumin-QingDai (CurQD) - A good treatment option for active ulcerative colitis?
Aliment Pharmacol Ther. 2023;58:640.
PubMed

DIGNASS A, Rath S, Kleindienst T, Stallmach A, et al
Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails-Authors' reply.
Aliment Pharmacol Ther. 2023;58:634-635.
PubMed

KEDIA S, Ahuja V
Editorial: If STRIDE-II is the hammer, then Crohn's disease and ulcerative colitis are not the same nails.
Aliment Pharmacol Ther. 2023;58:632-633.
PubMed

YANAI H, Salomon N, Ben-Horin S, Kopylov U, et al
Letter: Chinese herbal medicine Curcumin-QingDai (CurQD)-A good treatment option for active ulcerative colitis? Authors' reply.
Aliment Pharmacol Ther. 2023;58:641.
PubMed

August 2023

HONAP S, Peyrin-Biroulet L
Review article: Externally derived control arms-An opportunity for clinical trials in inflammatory bowel disease?
Aliment Pharmacol Ther. 2023 Aug 21. doi: 10.1111/apt.17684.
PubMed Abstract available

EVERHOV AH, Soderling J, Befrits G, Khalili H, et al
Increasing healthcare costs in inflammatory bowel disease 2007-2020 in Sweden.
Aliment Pharmacol Ther. 2023 Aug 18. doi: 10.1111/apt.17675.
PubMed Abstract available

WOELFEL S, Dutschler J, Konig M, Dulovic A, et al
STAR SIGN study: Evaluation of COVID-19 vaccine efficacy against the SARS-CoV-2 variants BQ.1.1 and XBB.1.5 in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Aug 12. doi: 10.1111/apt.17661.
PubMed Abstract available

LOBATON T, Truyens M
Editorial: LAG-3-depleting monoclonal antibody: a potential treatment for patients with ulcerative colitis?
Aliment Pharmacol Ther. 2023;58:359-360.
PubMed

KANE S
Editorial: Increased risk of cervical dysplasia with immunomodulator use in IBD.
Aliment Pharmacol Ther. 2023;58:357-358.
PubMed

KIRCHGESNER J, Beaugerie L
Editorial: Pip pip to PIPs (post- inflammatory polyps) as a neoplasia risk factor in IBD? Authors' reply.
Aliment Pharmacol Ther. 2023;58:363.
PubMed

TASSONE D, Hartley I, Ding NS
Letter: Combatting sarcopenia to improve clinical outcomes in inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;58:376-377.
PubMed

VELAYOS FS
Editorial: Pip pip to PIP's (post-inflammatory polyps) as a neoplasia risk factor in IBD?
Aliment Pharmacol Ther. 2023;58:361-362.
PubMed

July 2023

DENG M, Dan L, Ye S, Chen X, et al
Higher dietary fibre intake is associated with lower risk of inflammatory bowel disease: prospective cohort study.
Aliment Pharmacol Ther. 2023 Jul 18. doi: 10.1111/apt.17649.
PubMed Abstract available

MIN Y, Wei X, Peng X
Letter: Mendelian randomization-New perspective in inflammatory bowel disease and pancreatic cancer?
Aliment Pharmacol Ther. 2023;58:143-144.
PubMed

MASSIRONI S, Vigano C, Danese S
Letter: Mendelian randomization - new perspective in inflammatory bowel disease and pancreatic cancer? Authors' reply.
Aliment Pharmacol Ther. 2023;58:145-146.
PubMed

MILES M, Nasser Y
Editorial: faecal incontinence in ulcerative colitis.
Aliment Pharmacol Ther. 2023;58:114-115.
PubMed

CHAN P, Connor S, Huang V, Karimi N, et al
Letter: expanding the role for decision aids in IBD into pregnancy-related topics.
Aliment Pharmacol Ther. 2023;58:141-142.
PubMed

ESTEVINHO MM, Magro F
Editorial: elderly onset inflammatory bowel disease - clues from the largest population-based cohort study.
Aliment Pharmacol Ther. 2023;58:116-117.
PubMed

HUDSON AS, Huynh HQ
Editorial: Predicting paediatric ulcerative colitis outcomes-how can we improve?
Aliment Pharmacol Ther. 2023;58:258-259.
PubMed

OH SJ, Kim HJ, Lee CK
Editorial: Antibiotics and risk of IBD-Can we close the books? Authors' reply.
Aliment Pharmacol Ther. 2023;58:256-257.
PubMed

EBRAHIMI F, Forss A
Editorial: Antibiotics and risk of IBD-Can we close the books?
Aliment Pharmacol Ther. 2023;58:254-255.
PubMed

BACSUR P, Ilias A, Resal T, Kata D, et al
Letter: Experience of switching vedolizumab treatment from intravenous to subcutaneous formulation in Hungary.
Aliment Pharmacol Ther. 2023;58:262-263.
PubMed

June 2023

D'HAENS G, Peyrin-Biroulet L, Marks DJB, Lisi E, et al
A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis.
Aliment Pharmacol Ther. 2023 Jun 16. doi: 10.1111/apt.17557.
PubMed Abstract available

BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Efken P, et al
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naive patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDO(IBD) -study.
Aliment Pharmacol Ther. 2023 Jun 15. doi: 10.1111/apt.17616.
PubMed Abstract available

NGUYEN AL, Burns M, Herath M, Lambell K, et al
Accuracy of ultrasound, bioelectrical impedance analysis and anthropometry as point-of-care measurements of skeletal muscle mass in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Jun 12. doi: 10.1111/apt.17607.
PubMed Abstract available

KOCHHAR GS, Desai A, Farraye FA, Cross RK, et al
Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study.
Aliment Pharmacol Ther. 2023 Jun 9. doi: 10.1111/apt.17570.
PubMed Abstract available

MACALUSO FS, Orlando A
Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation?
Aliment Pharmacol Ther. 2023;57:1343-1344.
PubMed

CALDERA F, Spaulding AC, Hayney MS, Farraye FA, et al
Editorial: adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease-time for universal recommendation? Authors' reply.
Aliment Pharmacol Ther. 2023;57:1345-1346.
PubMed

CHEN P, Chen F
Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients.
Aliment Pharmacol Ther. 2023;57:1349-1350.
PubMed

IKEGAMI S, Nakamura M, Honda T, Kawashima H, et al
Letter: 1-kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients-authors' reply.
Aliment Pharmacol Ther. 2023;57:1351-1352.
PubMed

HANZEL J, Drobne D
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring.
Aliment Pharmacol Ther. 2023;57:1469-1470.
PubMed

SETHI S, Kumar A, Dias S, Blackwell J, et al
Editorial: proactive anti-TNF drug monitoring in IBD-Ready for the prime time? Authors' reply.
Aliment Pharmacol Ther. 2023;57:1455-1456.
PubMed

FUMERY M, Roblin X
Editorial: golimumab dosing intensification effective in ulcerative colitis with no need for therapeutic drug monitoring-author's reply.
Aliment Pharmacol Ther. 2023;57:1471-1472.
PubMed

ROBLIN X, Nancey S
Editorial: proactive anti-TNF drug monitoring in IBD-Ready for prime time?
Aliment Pharmacol Ther. 2023;57:1453-1454.
PubMed

POLLOK RC, Jayasooriya N, Baillie S, Blackwell J, et al
Letter: delays to diagnosis of IBD-Challenges requiring a systematic approach. Authors' reply.
Aliment Pharmacol Ther. 2023;57:1479.
PubMed

CHANG HC, Gau SY
Letter: histologic disease activity and colorectal neoplasia risk.
Aliment Pharmacol Ther. 2023;57:1480.
PubMed

LUCAS S, Chauhan A, Garg M
Letter: delays to diagnosis of IBD-Challenges requiring a systematic approach.
Aliment Pharmacol Ther. 2023;57:1477-1478.
PubMed

May 2023

ATIA O, Klomberg RCW, de Ridder L, Kemos P, et al
Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort.
Aliment Pharmacol Ther. 2023 May 29. doi: 10.1111/apt.17544.
PubMed Abstract available

KREIJNE JE, Goetgebuer RL, Erler NS, De Boer NK, et al
Cumulative exposure to immunomodulators increases risk of cervical neoplasia in women with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 May 23. doi: 10.1111/apt.17555.
PubMed Abstract available

YANAI H, Salomon N, Lahat A, Ungar B, et al
Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study.
Aliment Pharmacol Ther. 2023 May 8. doi: 10.1111/apt.17538.
PubMed Abstract available

OH SJ, Kim HJ, Lee CK
A dose-dependent increase in the risk of inflammatory bowel disease after exposure to broad-spectrum antibiotics: A national population study in Korea.
Aliment Pharmacol Ther. 2023 May 8. doi: 10.1111/apt.17542.
PubMed Abstract available

CHEN J, Ruan X, Yuan S, Theodoratou E, et al
Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation-authors' reply.
Aliment Pharmacol Ther. 2023;57:1034-1035.
PubMed

VAN RULER O, Arkenbosch JHC, van der Woude CJ
Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease. Authors' reply.
Aliment Pharmacol Ther. 2023;57:1030-1031.
PubMed

BURISCH J
Editorial: Why are patients with Crohn's disease still treated with 5-aminosalicylates?
Aliment Pharmacol Ther. 2023;57:1044-1045.
PubMed

DART RJ
Editorial: Heal thyself-Autologous therapy for perianal Crohn's disease.
Aliment Pharmacol Ther. 2023;57:1028-1029.
PubMed

MEYER A, Amiot A, Carbonnel F
Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisation.
Aliment Pharmacol Ther. 2023;57:1032-1033.
PubMed

CHEN J, Ruan X, Yuan S, Theodoratou E, et al
Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases-moving towards causal associations. Authors' reply.
Aliment Pharmacol Ther. 2023;57:1048-1049.
PubMed

GEERTSEMA S, van Goor H, Dijkstra G, Faber KN, et al
Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases - moving towards causal associations.
Aliment Pharmacol Ther. 2023;57:1046-1047.
PubMed

SONNENBERG A, Genta RM
Editorial: concurrence of coeliac disease with inflammatory bowel disease - is big data the final arbiter? Authors' reply.
Aliment Pharmacol Ther. 2023;57:1155-1156.
PubMed

SZIGETI R, Krishna M, Kellermayer R
Letter: fulminant-onset complicated inflammatory bowel disease (IBD)-a unique subtype?
Aliment Pharmacol Ther. 2023;57:1192-1193.
PubMed

POLLOK RC, Baillie S, Jayasooriya N, Blackwell J, et al
Letter: diagnostic delay in inflammatory bowel disease-Authors' reply.
Aliment Pharmacol Ther. 2023;57:1205-1206.
PubMed

ATIA O, Goren I, Yanai H
Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease-authors' reply.
Aliment Pharmacol Ther. 2023;57:1184-1185.
PubMed

ANDERSON RP
Editorial: concurrence of coeliac disease with inflammatory bowel disease - is big data the final arbiter?
Aliment Pharmacol Ther. 2023;57:1153-1154.
PubMed

TASSONE D, Gilmore R, Lee T, Ding NS, et al
Letter: diagnostic delay in inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;57:1203-1204.
PubMed

JAYASOORIYA N, Saxena S, Pollok RC
Letter: fulminant onset complicated inflammatory bowel disease (IBD) - a unique subtype? Authors' reply.
Aliment Pharmacol Ther. 2023;57:1194-1195.
PubMed

CHANG HC, Gau SY
Letter: 5-aminosalicylate maintenance treatment in mild Crohn's disease.
Aliment Pharmacol Ther. 2023;57:1183.
PubMed

April 2023

CASANOVA MJ, Nantes O, Varela P, Vela-Gonzalez M, et al
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
Aliment Pharmacol Ther. 2023 Apr 23. doi: 10.1111/apt.17525.
PubMed Abstract available

NORGARD BM, Zegers FD, Knudsen T, Kjeldsen J, et al
Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study.
Aliment Pharmacol Ther. 2023 Apr 20. doi: 10.1111/apt.17520.
PubMed Abstract available

BOKEMEYER B, Plachta-Danielzik S, di Giuseppe R, Helwig U, et al
Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5-year follow-up data from the prospective BioCrohn study.
Aliment Pharmacol Ther. 2023 Apr 13. doi: 10.1111/apt.17512.
PubMed Abstract available

GOLD SL, Raman M, Sands BE, Ungaro R, et al
Review article: Putting some muscle into sarcopenia-the pathogenesis, assessment and clinical impact of muscle loss in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Apr 13. doi: 10.1111/apt.17498.
PubMed Abstract available

OLIVERA PA, Lasa JS, Peretto G, Zuily S, et al
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
Aliment Pharmacol Ther. 2023 Apr 10. doi: 10.1111/apt.17509.
PubMed Abstract available

VASANT DH, Nigam GB, Bate S, Hamdy S, et al
The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross-sectional study.
Aliment Pharmacol Ther. 2023 Apr 3. doi: 10.1111/apt.17502.
PubMed Abstract available

GUPTA A, Kedia S, Ahuja V
Letter: trial of antitubercular therapy for diagnosing Crohn's disease in LMICs-double whammy?
Aliment Pharmacol Ther. 2023;57:815-816.
PubMed

SPEEDY AP, Wall CL
Editorial: Interdisciplinary and multidisciplinary approach to malnutrition in patients with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023;57:907-908.
PubMed

March 2023

WOLF T, Lewis A, Beaugerie L, Svrcek M, et al
Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post-inflammatory polyps.
Aliment Pharmacol Ther. 2023 Mar 31. doi: 10.1111/apt.17495.
PubMed Abstract available

CALDERA F, Spaulding AC, Borah B, Moriarty J, et al
Cost-effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease.
Aliment Pharmacol Ther. 2023 Mar 10. doi: 10.1111/apt.17454.
PubMed Abstract available

ATIA O, Goren I, Fischler TS, Weisband YL, et al
5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease-A nationwide cohort study.
Aliment Pharmacol Ther. 2023 Mar 9. doi: 10.1111/apt.17419.
PubMed Abstract available

MELTON SL, Taylor KM, Gibson PR, Halmos EP, et al
Review article: Mechanisms underlying the effectiveness of exclusive enteral nutrition in Crohn's disease.
Aliment Pharmacol Ther. 2023 Mar 9. doi: 10.1111/apt.17451.
PubMed Abstract available

February 2023

FUMERY M, Nancey S, Filippi J, Altwegg R, et al
Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.
Aliment Pharmacol Ther. 2023 Feb 27. doi: 10.1111/apt.17421.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum